Human Immunodeficiency Virus 12721 The 3 major routes of HIV transmission are sexual intercourse, contaminated needles, and transmission from an infected mother to her baby at birth, or through breast milk. HIV primarily infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. This decreases CD4+ T cells through direct viral killing of infected cells, increased rates of apoptosis in infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity (CMI) is lost, and the body becomes progressively more susceptible to opportunistic infections (Chan et al., 1997). Acquired Immunodeficiency Syndrome (AIDS) HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on target cells and also with chemokine coreceptors. Macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. T-tropic isolates, or syncitia-inducing (SI) strains replicate in primary CD4+ T cells as well as in macrophages. Dual-tropic HIV-1 strains are thought to be transitional strains of the HIV-1 virus. HIV can also infect a subtype of myeloid dendritic cells, which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels (Chan et al., 1997)(Coakley et al., 2005)(Deng et al., 1996)(Knight et al., 1990). AIDS has killed more than 25 million people since it was first recognized in 1981. Globally, ~40 million people currently live with HIV. Sub-Saharan Africa remains by far the worst-affected region. More than 64% of all people living with HIV are in sub-Saharan Africa, as are more than three quarters of all women living with HIV. Two-thirds of HIV/AIDS infections in Asia occur in India, with an estimated 6 million infections, surpassing South Africa's 5.5 million infections, making India the country with the highest number of HIV infections in the world (Palella et al., 1998). Human immunodeficiency virus (HIV) is the retrovirus that causes acquired immunodeficiency syndrome (AIDS). Within bodily fluids, HIV is present as both free virus particles and as virus within infected immune cells. So far, AIDS has killed more than 25 million people since it was first recognized in 1981, making it one of the most destructive pandemics in recorded history. Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries. Most HIV-infected individuals develop AIDS and die; however, about 10% remains healthy for many years, with no noticeable symptoms. Treatment with anti-retrovirals increases the life expectancy of people infected with HIV (Palella et al., 1998) (Buchbinder et al., 1994). Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 Adenoviral vector Ad5 expressing SIV gag protein VO_0000788 Recombinant vector vaccine Research Adenoviral vector (Ad5) Intramuscular injection (i.m.) The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002). Intramuscular injection (i.m.) SIVmac239 gag protein (Shiver et al., 2002) Recombinant vector construction In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002). rhesus monkey (Macaca mulatta) In this study, 21 rhesus monkeys were divided into 6 groups, including an unimmunized control cohort. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. In the first study, the two viral vector vaccines were administered, followed by a booster dose; preparations of DNA plasmid vector vaccine were delivered thrice, followed by a booster (Shiver et al., 2002). Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. With the exception of one animal, all of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002). At 12 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002). ALVAC-HIV-2 VO_0004727 Recombinant vector vaccine Research Intramuscular injection (i.m.) A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Intramuscular injection (i.m.) Recombinant vector construction Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Recombinant vector construction Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125 (Walther-Jallow et al., 2001). VO_0003057 After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection. Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001). The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally (Walther-Jallow et al., 2001). ALVAC-HIV-2- env/gag/pol VO_0004737 Recombinant vector vaccine Research Intramuscular injection (i.m.) A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Intramuscular injection (i.m.) Recombinant vector construction Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Recombinant vector construction Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001). Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001). VO_0003057 Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001). 7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001). ALVAC-SIV/gp120 VO_0004638 Recombinant vector vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) CVB4/p24(73(3)) VO_0004719 Recombinant vector vaccine Research Intramuscular injection (i.m.) A live coxsackievirus B4 recombinant, CVB4/p24(73(3)), that expresses seventy-three amino acids of the gag p24 sequence (HXB2) (Gu et al., 2010). Intramuscular injection (i.m.) Immunization was by intraperitoneal (IP) injection or by oral gavage. Mice were immunized with either CVB4/p24(733) or the parental CVB4. PBS-treated mice served as controls (Gu et al., 2010). VO_0003057 Results showed that oral immunization with CVB4/p24(73(3)) induced gag p24-specific immune responses in vector-immune mice (Gu et al., 2010). Mice immunized with the avirulent CVB4 variant are protected when subsequently challenged with a virulent variant (Gu et al., 2010). DNA and poxvirus priming-boosting SHIV vaccine VO_0000825 DNA vaccine pV1R plasmid and recombinant fowlpox virus An HIV vaccine should elicit a cytotoxic T lymphocyte (CTL) response, but the characteristics of effective vaccine-induced CTL response remain unclear. The SHIV/rhesus monkey model has been used to in the course of assessing the relative immunogenicity of vaccine regimens that include a cytokine-augmented plasmid DNA prime and a boost with DNA or recombinant pox vectors. This study indicates that the steady-state memory, rather than the peak effector vaccine-elicited CTL responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004). IL-2/Ig (Santra et al., 2004) The recombinant vaccinia viruses (rVac) expressing SHIV89.6P env and SIVmac239 gag were constructed by inserting these genes in the HindIII M region of TBC-Wy, Therion strain of vaccinia. rFPV viruses expressing these same genes were constructed by inserting the genes in the BamJHI region of POXVAC-TC (Schering-Plough) strain of FPV (Santra et al., 2004). SHIV89.6P env and SIVmac239 gag (Santra et al., 2004) DNA vaccine construction DNA vaccine construction Recombinant vaccinia virus, MVA, and fowlpox were comparable in their immunogenicity. Magnitude of peak vaccine-elicited CTL responses in pox virus-boosted monkeys is substantially greater than that seen in monkeys immunized with plasmid DNA alone, but magnitudes of recombinant pox boosted CTL responses decayed rapidly and were comparable to those of the DNA-alone vaccinated monkeys by the time of viral challenge. Clinical protection seen in all groups of experimentally vaccinated monkeys is similar, indicating that steady-state memory, rather than peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004). rhesus monkey (Macaca mulatta) Nonrecombinant wildtype vaccinia virus was designated VV-WT, wild-type fowlpox virus was designated FPV-WT, and wild-type MVA was designated MVA-WT. These wild-type viruses were used as control vector immunogens (Santra et al., 2004). One group of monkeys were vaccinated by separate i.m. injections of HIV-1. Half the dose was delivered to each quadriceps muscle. Seven of the 28 monkeys were vaccinated by both i.d. and i.m. injections of rFPV expressing HIV-1 89.6P Env and the same virus expressing SIV mac239 Gag. Seven monkeys received rMVA-HIV-189.6P Env and rMVA-SIVmac239 Gag, and another seven monkeys received rVac-HIV-1 89.6P Env and rVac-SIVmac239 Gag administered both i.d. and i.m. Another 28 monkeys received sham plasmid DNA and empty pox vectors (Santra et al., 2004). Persistence levels were measured 2 weeks after challenge with results mentioned in Challenge Protocol section (Santra et al., 2004). Control monkeys developed tetramer-binding CD8 T lymphocyte responses that were maximal 2 weeks after viral challenge and no detectable p41A-specific CD8 T cells. In contrast, all four groups of vaccinated monkeys developed robust secondary p11C-specific CTL responses that were comparable in magnitude. Animals boosted with plasmid DNA had Gag p11C-specific CD8 T cell responses similar in magnitude to that seen in the recombinant pox virus-boosted animals. Magnitudes of the postchallenge IFN ELISPOT responses to both vaccine antigens were comparable in all four experimentally vaccinated groups of monkeys. Therefore, although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004). Eighteen weeks after the final immunization, all animals were challenged with cell-free SHIV-89.6P i.v. (Santra et al., 2004). There was a greater contraction of the vaccine-elicited IFN-γ-secreting T cell responses in the groups of monkeys boosted with recombinant pox vectors than in the group of animals boosted with plasmid DNA. Although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004). DNA vaccine expressing multiple HIV epitopes VO_0000817 DNA vaccine Auxo-GTU vector system [Ref319:Malm et al., 2005] A significant limitation for HIV vaccine development is that there are no small animals in which actual productive HIV-1 infection can be established. DNA immunization with candidate vaccines comprising multiple genes of clades A, B, C, F, G, and H create strong cellular responses in BALB/c mice, especially after gene gun immunization (Malm et al., 2005). A vaccine platform was constructed with an HIV-1 subtype B DNA immunogen expressing full-length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences (Malm et al., 2005). The antigens are named MultiHIV-A (based on the subtype A consensus sequence), MultiHIV-B (subtype B consensus sequence), MultiHIV-C, and MultiHIV-FGH (based on ancestral sequence for subtypes F, G, and H). The MultiHIV DNAs encode polypeptides consisting of a fusion of the full-length regulatory proteins Rev, Nef and Tat as well structural proteins p17 and p24 (Malm et al., 2005). DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction Though the immune response detected was quite low, the majority of g.g. immunized animals responded with specific IFN production. Interestingly, the gag specific response in the same gene gun immunized animals was weaker than the envelope responses and also drastically weaker than the responses seen before the experimental challenge (Malm et al., 2005). The CTL response, following i.d. injection, was detected five weeks after the first immunization and persisted up to 12 weeks later. In contrast, i.m. immunization induced detectable IFNy only at week 17 (Malm et al., 2005). C57BL/6, BALB/c C57BL/6 mice were divided into groups g.g. immunized or i.m. inoculated. Mice were bled 2 weeks after the last immunization, and individual blood and spleen samples were collected post-challenge and used fresh in ELISPOT assays (Malm et al., 2005). BALB/c were immunized by MultiHIV/MultiClade DNA. Initially the immune response was evaluated after 3 immunizations by g.g. Equal amounts of clade A, B, C, and FGH MultiHIV plasmids were mixed together and coated onto the gold particles to construct the subtype cocktail MultiHIV DNA immunogen (MultiHIVmix). Mice were sacrificed 10 days after the last immunization and individual spleens were collected and the cells preserved at –70°C until used. In a second set of experiments a short-term immunization schedule was used to address three different administration routes; g.g., i.m., and i.d. Mice were immunized 3 times with MultiHIVmix DNA (Malm et al., 2005). The vaccine-induced immunity has in vivo efficacy. Here a mouse model showed that the HIV-1 GTU-MultiHIVmix vaccine induces virus-specific CD8 T cellular immunity and protects against experimental HIV-1 challenge (Malm et al., 2005). no side effects occurred (Malm et al., 2005) C57BL/6 mice transgenic for HLA-A201 were given an experimental challenge after a short-term immunization schedule. Amphotropic murine leukemia virus was used to prepare pseudovirus with HIV-1 isolate. Challenged animals were given i.p. injections of sHIV-1/MuLV infected cells (Malm et al., 2005). The cocktail of MultiHIV protected 19/24 animals against an experimental HIV-1 challenge. This experiment also demonstrates cross-clade protection, as the subtypes A and B viruses used for challenge were derived from different subtypes than the sequences found in the clade A or B specific MultiHIV constructs. Furthermore, it demonstrates that consensus approach used in Multi-HIVmix vaccine is functional and causes protection against naturally occurring isolates. Gene gun immunization was superior to intramuscular immunization in terms of both the T cell immunity induced, as well as higher frequency of protection. Data generated in this work support the hypothesis that DNA representing several HIV-1 subtypes and several genes are immunogenic and protective (Malm et al., 2005). IFN-gamma levels in mice immunized by gene gun or intramuscular delivery with HIV-1 subtype B DNA immunogen showed strong up regulation in response to an H-2d restricted gag peptide (AMQMLKETI) and even stronger up-regulation in response to an env epitope (RGPGRAFVTI) (Malm et al., 2005). Gag-VRPs VO_0000822 VEE replicon particles (VRPs) Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). Structural proteins for packaging of replicon RNA into VRPs are expressed from separate helper RNAs. VRPs expressing either the matrix-capsid portion of Gag, the full-length envelope gp160, or the secreted gp140 of cloned SIVsm H-4i were mixed in a cocktail and used to immunize macaques (Davis et al., 2002). HIV matrix-capsid portion of Gag, envelope gp160, secreted gp140, cloned SIVsm H-4i, SIVsm E660 (Davis et al., 2002) In BALB/c mice, the two vectors elicited cellular immune responses to MA/CA as determined by bulk CTL assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999). BALB/c VRPs with wild-type glycoprotein spikes were inoculated into the footpads of mice (Davis et al., 2002). At 11 months post-boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999). Both humoral and cellular immune responses were induced. On the day of challenge, all vaccinated animals had neutralizing antibody to the homologous SIVsm H-4, most had CTL specific for Gag, Env, or both. The animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Peak virus titers in plasma were reduced, and the range of peak titers was much smaller for the controls, suggesting that a clear protective effect against the acute phase of infection was induced in some of the vaccinated animals (Davis et al., 2002). rhesus monkey (Macaca mulatta) A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140) was used to immunize rhesus macaques. Animals were given each VRP subcutaneously in the arm and later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs (Davis et al., 2002). Animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Four of six vaccinated animals, as compared to one of six controls, showed virus loads below 1,700 copies per ml at the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Most vaccinated animals showed virus loads below the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Finally, the CD4C cells of the vaccinated animals were preserved and even increased postchallenge compared to those of the controls. In fact, in the vaccinated animals, there is a clear correlation between increased CD4C cells and lowered viral load (Davis et al., 2002). No side effects were encountered (Davis et al., 2002). Animals were given a dose of VRP subcutaneously in the arm and 1 month later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs. The challenge virus was the highly virulent swarm SIVsm E660 (Davis et al., 2002). gp120 recominant with GMDP adjuvant VO_0004233 Subunit vaccine Research subcutaneous injection subcutaneous injection Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992). Mice immunized with gp120 and GMDP in combination with pluronic emulsion resulted in a secondary antibody response (Bomford et al., 1992). BALB/c Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992). gp120 recominant with MDP adjuvant VO_0004234 Subunit vaccine Research subcutaneous injection subcutaneous injection Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992). Mice immunized with gp120 adjuvanted with MPD plus pleuronic emulsion resulted in a secondary antibody response (Bomford et al., 1992). BALB/c Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992). gp140, Gag and Tat Protein Vaccine with MF59 VO_0004238 Subunit vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) gp140, Gag and Tat recombinant proteins (Bråve et al., 2007). C57Bl/6 The protein vaccine component consisted of 20 μg ro-gp140 delivered in the right tibialis muscle and 20 μg rGag and 5 μg rTat delivered in the left tibialis muscle. The proteins were formulated in 50% MF59 solution. Mock treatment consisted of MF59 adjuvant alone or empty DNA plasmid alone (Bråve et al., 2007). 83% of mice were tested negative for HIV-1 after challenge (Bråve et al., 2007). Briefly, 3 weeks after the final immunization (week 12), the animals were injected intraperitoneally with 1 million syngeneic splenocytes infected with HIV-1/MuLV of subtype B (LAI) (Bråve et al., 2007). HIV DNA and adenoviral vector Ad5 expressing SIV gag protein VO_0000786 DNA vaccine Research V1R plasmid and adenoviral vector (Ad5) Intramuscular injection (i.m.) Immunization and viral challenge studies were conducted in rhesus macaques (Macaca mulatta). Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The plasmid DNA vector was formulated in either PBS solution, a solution containing adjuvant, or a solution containing MPL/alum. All immunized animals were genotyped for the MHC class I Mamu-A*01 allele, allowing analysis of the responses of T cells (CD8+) to the test vaccines (Shiver et al., 2002). CRL1005 for DNA vaccine (Shiver et al., 2002) No virulence has been reported associated with this vaccine (Shiver et al., 2002). The V1R DNA vector expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells (Shiver et al., 2002). The plasmid DNA vector was formulated in a solution containing a nonionic blocked copolymer adjuvant (CRL1005) (Shiver et al., 2002). The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002). Intramuscular injection (i.m.) SIVmac239 gag protein (Shiver et al., 2002) Recombinant vector construction DNA vaccine construction In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002). rhesus monkey (Macaca mulatta) This study used 14 monkeys, 3 each in the immunized groups and 8 in the unimmunized control group. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The DNA vector priming inoculations were administered, followed by viral vector boost inoculations (Shiver et al., 2002). Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. All of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors or with the DNA/CRL1005–MVA vector prime–boost combination exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002). None of the vaccinated monkeys have yet exhibited any signs of immunodeficiency or suffered any consistent weight loss (Shiver et al., 2002). At 6 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002). Levels of interferon-gamma in monkeys stimulated intramuscularly with either the p11CM peptide or a pool of peptides derived from SIV gag were significantly upregulated and correlated well with the tetramer-staining results after the final boost. Intracellular IFN-[gamma]-staining assays confirmed that these responses were primarily mediated by CD8+ T cells (Shiver et al., 2002). HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag VO_0004342 Recombinant vector vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant vector construction This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012). DNA vaccine construction This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012). Recombinant vector construction This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012). DNA vaccine construction This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012). VO_0000286 After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected. In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012). HIV DNA vaccine pCMN160 VO_0004345 DNA vaccine Research pCMN160 [Ref2214:Boyer et al., 1997] Intramuscular injection (i.m.) Intramuscular injection (i.m.) env and rev of HIV-1 strain MN and gag/pol from HIV-1 III8 (Boyer et al., 1997) DNA vaccine construction This DNA vaccine encoded env (Boyer et al., 1997). DNA vaccine construction This DNA vaccine encoded rev (Boyer et al., 1997). DNA vaccine construction This DNA vaccine encoded gag/pol from HIV-1 III8 (Boyer et al., 1997). VO_0000286 Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus. Polymerase chain reaction coupled with reverse transcription results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection (Boyer et al., 1997). HIV DNA vaccine pHIS-SHIV-B VO_0004348 DNA vaccine Research pHIS-64 [Ref2227:Dale et al., 2004] Intramuscular injection (i.m.) Intramuscular injection (i.m.) full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004) DNA vaccine construction The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004). DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction VO_0000286 DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004). SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004). HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) VO_0004344 DNA vaccine Research pGA [Ref2205:Robinson et al., 2006] Intramuscular injection (i.m.) GM-CSF (Robinson et al., 2006) Intramuscular injection (i.m.) DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P (Robinson et al., 2006). VO_0000286 The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection (Robinson et al., 2006). HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost VO_0004349 DNA vaccine Research pVR1012 prime, rAd5 boost [Ref2230:Mascola et al., 2005] Intramuscular injection (i.m.) Intramuscular injection (i.m.) DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA priming-rAd5 boosting immunization platform can elicit potent anti-HIV-1 cellular immune responses and anti-HIV-1 neutralizing antibodies (Mascola et al., 2005). VO_0000286 In a challenge study, all monkeys were immunized with DNA plasmids at 0, 4, and 8 weeks and boosted with rAd5 at week 26. Serial plasma dilutions were tested against four of the more neutralization-sensitive viruses, and the plasma dilution that produced 50% virus neutralization, which is required to protect 50% of the cells from virus-induced killing, was determined. The data clearly demonstrates that both the vaccine platform and these immunogens elicit IgG-mediated virus neutralization (Mascola et al., 2005). HIV DNA vaccine VlJns-tPA-gp120 VO_0004351 DNA vaccine Research VlJns [Ref2235:Lekutis et al., 1997] Intramuscular injection (i.m.) Intramuscular injection (i.m.) DNA vaccine construction This vaccine encoded gp120 from HIV IIIB (Lekutis et al., 1997). The secretion of IFN-y stimulated CD4+ Th cell lines and rgp120-stimulated PBL from the vaccinated monkeys suggest that an HIV-1 env plasmid DNA vaccine elicits a Thl-like immune response in primates as well as in rodents (Lekutis et al., 1997) VO_0000286 The secondary immune response that arose after repeated plasmid DNA administration was Thl-like, suggesting that the nature of the DNA vaccine-elicited Th cell response was maturation dependent. Evidence from vaccinated nonhuman primates suggests that a vigorous Th cell response, including viral Ag-specific IFN-y production, may be a correlate of protection from HIV- 1 and Simian Human Immunodeficiency Virus infection (Lekutis et al., 1997) HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein VO_0000789 DNA vaccine pCAGGS and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) Replication-defective Ad5 HIV recombinants and replication-defective MVA elicit potent CD8+ T-cell responses and provide a high degree of protection in NHPs. The Ad5 (subgroup C) has well-defined biological properties and has been widely used as a vector for gene therapy and vaccine. The replication-defective Ad5 vector can easily be produced in high titers and is highly effective in boosting HIV-specific immunity. However, this virus uses CAR as its primary attachment receptor, which confers tropism for liver parenchymal cells. This raises important safety concerns. Thus, a replication-defective chimeric Ad5 vector with Ad type 35 fiber (Ad5/35) has been developed, which not only induces strong antigen-specific humoral and cellular immune responses and exhibits minimal hepatotoxicity in both mice and NHPs, but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005). This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector (Xin et al., 2005). A replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) was prepared and used to express HIV Env gp160 protein. The product is named Ad5/35-HIV (Xin et al., 2005). HIV Env gp160 protein (Xin et al., 2005) Recombinant vector construction An Ad5/35 vector was used to express HIV Env gp160 protein (Ad5/35-HIV) (Xin et al., 2005). DNA vaccine construction The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005). DNA vaccine construction The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005). A detectable HIV-specific serum Ab response developed within 2 weeks of the first immunization. At 4 weeks post boosting, titers in excess of 1:50 000 were achieved. Similar results were observed in neutralizing Ab. A increase in the number of HIV-specific IFN-gamma-secreting T cells was also detected in the peripheral blood mononuclear cells (PBMCs). Boosting with Ad5/35-HIV vector further increased this T-cell response (Xin et al., 2005). rhesus monkey (Macaca mulatta) 10^11 vp of Ad5/35-HIV vector was injected i.m. into two rhesus monkeys (2 years old, male) at weeks 0 and 8 (Xin et al., 2005). Liver infection with Ad5 vector was 20- to 40-fold stronger than that with Ad5/35 vector. Ad5-Luc vector was two- and four-fold higher, respectively, than that of the monkeys that received the Ad5/35-Luc vector. The Ad5/35 recombinants exhibits minimal hepatotoxicity in non-human primates but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005). The animals immunized with Ad5/35-HIV vector developed a high-titered anti-gp160 antibody (Ab) response. The magnitude of this response was not significantly altered by preimmunization with the DNA-HIV vaccine. DNA-HIV vaccination alone generated a low level of HIV-specific serum Ab. HIV-specific neutralizing Ab was only detectable in the Ad5/35-HIV vaccinated mice and DNA prime/Ad5/35-HIV boosted mice. HIV-specific cellular immune responses persisted through 7 months after final immunization (Xin et al., 2005). Mice were injected i.m. with Ad5-Luc or Ad5/35-Luc. Luciferase expression was monitored using an in vivo imaging system (IVIS). The expression of HIV gp160 was confirmed by Western blotting. Mice were immunized with Ad5/35-HIV vector, and the HIV-specific CMI was periodically monitored by the intracellular cytokine staining (ICS) assay (Xin et al., 2005). The animals that were vaccinated with the Ad5/35 vector alone or in combination with the DNA-HIV vaccine were completely protected from infection; however, the DNA-HIV vaccination alone had little impact on the susceptibility to infection by vPE16. DNA-HIV vaccination by itself was not protective, but the combination of DNA-HIV priming and Ad5/35-HIV boosting yielded a prolonged and complete protection (Xin et al., 2005). The hepatotoxicity caused by the Ad5 vector was circumvented by the use of an Ad5/35 vector (Xin et al., 2005). Immunized mice were challenged with vPE16 2 weeks after final immunization. Vaccinated mice were challenged with vPE16 7 weeks after final immunization. The strain vPE16 is HIVBH8 gp160-expressing replication-competent vaccinia virus (WR strain, vPE16; HIVBH8 gp160 has 97.32% amino-acid homology with HIVIIIB gp160) (Xin et al., 2005). HIV recombinant gp160 Protein Vaccine VO_0004274 Subunit vaccine Research subcutaneous injection subcutaneous injection Recombinant gp160 (Barrett et al., 1989). The highest potency in mice was obtained using a preparation with 0.2% Al(OH)3 and 0.25% deoxycholate (Barrett et al., 1989). The potency of the vaccine was determined by injecting mice with serial dilutions of gp160 alone or adjuvanted with different formulations. Groups of 10 mice were injected subcutaneously with 1 ml of fourfold dilutions of the test substance. A total of 50 mice were injected in each test (Barrett et al., 1989). HIV recombinant vector vaccine MVA-gag encoding gag VO_0004347 Recombinant vector vaccine Research pSC59 [Ref2225:Casimiro et al., 2003]. Intramuscular injection (i.m.) CRL1005 (Casimiro et al., 2003) Intramuscular injection (i.m.) Recombinant vector construction This recombinant vector vaccine expressed gag from HIV-1 (Casimiro et al., 2003). Immunization of macaques with MVA-gag resulted in relatively weak antigen-specific T-cell responses; the levels did not exceed 150 spot-forming cells (SFC)/106 PBMCs after three doses and were significantly less than those observed in the Ad5-gag vaccinees. Only one of six MVA-gag vaccinees elicited any detectable Gag-specific antibody response (140 mMU/ml at 4 weeks post-dose 3 for monkey V215) (Casimiro et al., 2003). VO_0000286 The study reports that SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors is able to inhibit viral replication and disease progression in rhesus macaques following challenge with the SHIV89.6P virus. However, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia (Casimiro et al., 2003). HIV recombinant vector vaccine MVA.HIVA encoding env and rev VO_0004350 Recombinant vector vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant vector construction This DNA vaccine encoded env from HIV-1 (Peters et al., 2007). Recombinant vector construction This DNA vaccine expressed rev from HIV-1 (Peters et al., 2007). HIV-1 gp120 with mCT E112K VO_0004268 Subunit vaccine Research intranasal immunization intranasal immunization HIV-1LAIEnv gp120 (Yoshino et al., 2004). Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4(+)) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups (Yoshino et al., 2004). rhesus macaques Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbancy with head tilted back so that the nares were pointed upward. Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbancy until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56 (Yoshino et al., 2004). Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004). Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated gp120-specific IgG responses with virus-neutralizing activity in both their plasma and mucosal external secretions compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004). Vaccinated animals that received the adjuvant had a greater increase in IL-4-producing Th2-type CD4-positive (CD4(+)) T cells in mesenteric lymph nodes (MLNs) than did controls vaccinated without the adjuvant, which did not produce IL-4 (Yoshino et al., 2004), HIV-2 DNA vaccine VO_0004259 DNA vaccine Research pND-14 [Ref2023:Locher et al., 2004] Intramuscular injection (i.m.) Intramuscular injection (i.m.) The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004). DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction Each baboon was immunized four times with the experimental or control DNA constructs formulated with Vaxfectin. The time intervals were chosen to permit maturation of the immune response (Locher et al., 2004). At 2 weeks post-HIV-2 challenge, viral loads ranged from 100 (below the threshold of detection) to 81,000 viral RNA copies in the plasma, with the lowest average viral loads in the group of baboons that received the HIV-2 DNA without the genetic adjuvants (a mean of 852 copies/ml), followed by the group of baboons the received the HIV-2 DNA and the genetic adjuvants (a mean of 2499 copies/ml) (Locher et al., 2004). One month after the fourth immunization, the baboons were challenged twice (6 h apart) by the intravaginal route using 50 baboon infectious dosages (30,000 tissue culture infectious dosages) of HIV-2UC2/9429 for a total of 100 baboon infectious dosages. This virus isolate is a more virulent variant of the HIV-2UC2 isolate and was recovered from a baboon with an AIDS-like disease (Locher et al., 2004). Inactivated HIV-2 Vaccine with PMMA VO_0004242 Inactivated or "killed" vaccine Research subcutaneous injection subcutaneous injection Mice immunized with PMMA adjuvant had higher antibody counts than mice immunized with an alum adjuvant (Stieneker et al., 1991). NMRI Mice received 0.5 ml of the specified vaccine preparations subcutaneously under the abdominal skin on day 0 (Stieneker et al., 1991). L. T -HIV-1 Gag VO_0004629 Recombinant vector vaccine Research [Ref3082:Breton et al., 2007] Intramuscular injection (i.m.) A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007). Intramuscular injection (i.m.) Recombinant vector construction A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007). Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag (Breton et al., 2007). Balb/c VO_0003057 Immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection (Breton et al., 2007). licensed acquired immunodeficiency syndrome human vaccine Generic Unknown VO_0000295 Subunit vaccine Licensed A generic representation of vaccines developed to prevent acquired immunodeficiency syndrome (AIDS) in humans, typically utilizing purified HIV proteins or protein fragments to elicit an immune response. These vaccines aim to stimulate protective immunity without using live or whole virus particles. MVA expressing HIV Gag, Pol and Env proteins VO_0000824 Recombinant vector vaccine modified vaccinia Ankara (MVA) An rMVA vaccine that expresses HIV Gag, Pol, and Env proteins was constructed (Liu et al., 2006). HIV Gag, Pol, and Env proteins (Liu et al., 2006) CD8 T cells were boosted more effectively than CD4 T cells with the ratio of elicited CD8 to CD4 cells for the immunodominant CD8 epitope in Gag increasing with boosts. The most effective boost for CD8 T cells resulted in the greatest skewing of the CD8 to CD4 T cell ratio. This could represent better access of CD8 than CD4 T cells to APCs (Liu et al., 2006). The dose–response studies showed good increases for antigen expression with increasing MVA dose. A 1000-fold increase in the dose of MVA resulted in a 300-fold increase in the frequency of antigen-expressing cells. In contrast, dose–response studies for in vivo immunogenicity showed <10-fold increases in elicited T cells and Ab for 100–1000-fold increases in the dose of inoculated MVA. Shallow dose–response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime (Liu et al., 2006). BALB/c Female BALB/c mice were used for immunizations. All were conducted on anesthetized mice. Immunizations with MVAs were accomplished by inoculating the desired amount of MVA into a single quadriceps muscle. Immunizations with DNA were accomplished by injecting the desired amount of DNA into the quadriceps, half in each leg (Liu et al., 2006). Temporal CD8 responses were conducted in BALB/c mice using MVA. Responses were steady for >10 weeks (>6 weeks post-MVA) (Liu et al., 2006). No adverse effects were encountered (Liu et al., 2006). NYVAC-HIV-1 VO_0004774 Recombinant vector vaccine Research Intramuscular injection (i.m.) Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000). Intramuscular injection (i.m.) Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000). VO_0000287 Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques (Patterson et al., 2000). One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000). NYVAC-HIV-2 VO_0004775 Recombinant vector vaccine Research Intramuscular injection (i.m.) Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000). Intramuscular injection (i.m.) Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000). VO_0003057 Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls (Patterson et al., 2000). One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000). NYVAC-SIV VO_0004779 Recombinant vector vaccine Research Intramuscular injection (i.m.) The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998). Intramuscular injection (i.m.) The macaques were immunized with NYVAC-SIV and NYVAC-IL-12 or NYVAC-SIV alone (Benson et al., 1998). VO_0003057 Significantly, five of the eleven vaccinees exposed mucosally to SIV(mac251) showed a transient peak of viremia 1 week after viral challenge and subsequently appeared to clear viral infection. In contrast, all 12 animals inoculated intravenously became infected, but 5 to 6 months after viral challenge, 4 animals were able to control viral expression and appeared to progress to disease more slowly than control animals. Protection did not appear to be associated with any of the measured immunological parameters. Further modulation of immune responses by coadministration of NYVAC-cytokine recombinants did not appear to influence the outcome of viral challenge (Benson et al., 1998). At the end of the immunization regimen, half of the animals were challenged with SIV(mac251) by the intravenous route and the other half were exposed to SIV(mac251) intrarectally (Benson et al., 1998). rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine VO_0004600 Recombinant vector vaccine Research Mycobacterium bovis bacillus Calmette-Guérin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) [Ref2794:Ami et al., 2005] Intramuscular injection (i.m.) Intramuscular injection (i.m.) gag from simian immunodeficiency viruses Recombinant vector construction The SHIV gag gene was inserted to a recombinant BCG vector and a replication-deficient vaccinia virus strain (DIs) vaccine vector (Ami et al., 2005). cynomologus macaque cynomologus macaques were primed with rBCG-SIVgag, and then boosted with rDIsSIVgag (Ami et al., 2005). VO_0003057 For the prime-boost vaccination group, plasma viremia levels remained undetectable and CD4+ T-cell counts stayed above 500 cells/μl for the entire year of testing (Ami et al., 2005). Ten weeks after the second booster immunization, the macaques were challenged by intrarectal inoculation with 2 × 10^3 TCID50 or 50 50% monkey infectious doses (MID50) of SHIV KS661c, an SHIV-89.6 variant clone (Ami et al., 2005). Recombinant HIV gp120 with adjuvant NanoEmulsion VO_0000819 Subunit vaccine An oil-in-water nanoemulsion (NE) (Bielinska et al., 2008). The gp120 and NE vaccines were prepared by mixing NE with gp120 protein solution, using pyrogen-free saline as a diluent (Bielinska et al., 2008). HIV glycoprotein 120, which has a role in facilitating coreceptor interaction and in mediating virus binding to cellular CD4 (Bielinska et al., 2008). Immunized mice demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA . The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008). BALB/c BALB/c mice were immunized with two or three intranasal administrations of gp120/NE formulation at 3 weeks apart. The immunizations of 10 microliters were performed by slowly applying gp120/NE mixes to the nares.Control mice were immunized with gp120 in saline, with NE alone or saline. Intramuscular immunization was performed with two doses, 3 weeks apart, of 20 micrograms of gp120 injected in 50 microliters of either saline or 1% NE (Bielinska et al., 2008). Immunization produced significant levels of serum anti-gp120 IgG antibodies in all animals, as was seen with the mice. The analysis of gp120-specific CTL proliferation, INF gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008). Hartley Hartley guinea pigs were immunized intranasally with two administrations (50 microliters per nare) of gp120/NE mix at 3 weeks apart (Bielinska et al., 2008). rgp120 HIV Vaccine with immunoliposomes VO_0004264 Subunit vaccine Research subcutaneous injection subcutaneous injection rgp120 (Ozpolat et al., 1998). Mice vaccinated with immunoliposomes were found to have a strong delayed-type hypersensitivity (DTH) response to the weakly immunogenic gp120 that was dependent on the presence of the MAbs. However, this vaccination protocol did not induce humoral immunity (Ozpolat et al., 1998). C3H/HeN Groups of five mice were immunized subcutaneously three times at 14-day intervals. The immunoliposomes were suspended in PBS and each mouse received 0.1 ml per injection. Each injection contained 380 &mu;g of PC, 193 &mu;g of CH, 10 pg of PE-B, 2.0 &mu;g of MAb, and 10 &mu;g of rgpl20 (Ozpolat et al., 1998). rMVA-SIV-CD40L VO_0004792 Recombinant vector vaccine Research Intramuscular injection (i.m.) Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014). Intramuscular injection (i.m.) The macaques were divided into 3 groups and group 1 was vaccinated with a DNA/MVA SIV vaccine, group 2 was vaccinated with the DNA/MVA SIV vaccine with CD40L in the DNA, and the third group was an unvaccinated control (Kwa et al., 2014). VO_0003057 CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection and improved viral control. Notably, the CD40L adjuvant enhanced the control of viral replication in the gut at the site of challenge that was associated with lower mucosal CD8 immune activation, one of the strong predictors of disease progression (Kwa et al., 2014). The macaques were intrarectally challenged with SIVE660 at a dose of 5000 TCID to test the level of protection of the vaccines (Kwa et al., 2014). rMVTT-SIV-gpe VO_0004760 Recombinant vector vaccine Research Intramuscular injection (i.m.) (Sun et al., 2013) a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe)) Intramuscular injection (i.m.) Recombinant vector construction A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013). Recombinant vector construction A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013). Recombinant vector construction A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013). Eight monkeys were divided into two groups: (i) four monkeys received the MVTTioin+Adim testing regimen as in study I, and (ii) four monkeys received an empty MVTT control vector (10^9 PFU) through intraoral (0.5 ml) and intranasal (0.5 ml) routes and an empty Ad5 control vector (10^11 vp in 1 ml of PBS) through intramuscular injection (Sun et al., 2013). VO_0003057 The reductions in peak and set-point viral loads were significant in most animals, with one other animal being protected fully from high-dose intrarectal inoculation of SIV(mac239). Furthermore, the animals vaccinated with this regimen were healthy, while ~75% of control animals developed simian AIDS. The protective effects correlated with the vaccine-elicited SIV-specific CD8(+) T cell responses against Gag and Pol (Sun et al., 2013). At either week 30 after the initial vaccination or week 24 after the final vaccination, each animal was challenged intrarectally with 5 × 10^5 50% tissue culture infective doses (TCID50) of Chinese rhesus monkey-adapted and neutralization-resistant SIVmac239. In all cases, the challenge virus stock was administered in 1 ml of PBS (Sun et al., 2013). SHIV DNA vaccine encoding env and gag VO_0004596 DNA vaccine Research pSW3891 [Ref2784:Pal et al., 2006] Gene gun Gene gun DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction VO_0003057 The immune response elicited by the multivalent DNA prime/protein boost vaccine was able to protect macaques from rectal challenge with SHIV-Ba-L isolate. This polyvalent vaccine formulation was able to confer protection in four out of six animals against SHIV-Ba-L and significantly reduced plasma viremia in the two remaining animals (Pal et al., 2006). SHIV(Ba-L) DNA vaccine encoding env and gag VO_0004597 DNA vaccine Research pSW3891 [Ref2786:Pal et al., 2005] Intramuscular injection (i.m.) Intramuscular injection (i.m.) DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction DNA vaccine construction VO_0003057 one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIV(Ba-L) (Pal et al., 2005). V3 VLPs with Gamma inulin adjuvant VO_0004232 Subunit vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) gp120 V3 loop (Harris et al., 1996). Mice immunized with V3 VLPs adjuvanted with gamma inulin showed good CTL responses (Harris et al., 1996). BABL/c Mice were immunized with 10 μg of V3-VLPs without adjuvant in the muscle of the left leg. At the same time, the mice were immunized in the right leg with the other immunogens (Harris et al., 1996). YF17D- HIV-1 p24 VO_0004690 Recombinant vector vaccine Research Intramuscular injection (i.m.) HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24) (Franco et al., 2010). Intramuscular injection (i.m.) Mice were immunized two times subcutaneously at the base of the tail with PBS or 10^6 pfu of YF17D, YF-E/p24/NS1, or YF-5′/p24 in 100 μl on days 0 and 14 (Franco et al., 2010). VO_0003057 The protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated (Franco et al., 2010). Three weeks after the second immunization, half of the mice in each group were challenged intranasally with 5 × 10^5 pfu of Gag-expressing recombinant vaccinia virus (Vac-gag). The remaining animals in the groups were challenged intranasally with the same dose of wild-type vaccinia virus (Vac-wt) (Franco et al., 2010). env Human immunodeficiency virus 1 isolate 715 from Baltimore clone 6 475647 CDD:278917 CDD:295533 CDD:197369 11676 ? envelope glycoprotein 8.4 91460.08 942 Envelope glycoprotein GP120; pfam00516 >AAB04079.1 envelope glycoprotein, partial [Human immunodeficiency virus 1] VTGIRKNCQHWWKWGIMLLGILMICNATEKLWVTVYYGVPVWKEANTTLFCASDAKAYDTEVHNVWATHA CVPTDPDPQEVELENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNLRNDTNTTRN ATNTTSSETMMEEGEIKNCSFNITTSIRDKVQKEFALFYKLDVVPIENDTTSYRLISCNTSVLTQACPKV SFEPIPIHFCAPAGFAILKCKDKKFNGTGPCTNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSANLS DNAKTIIVQLNESVQMNCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRTKWNETLKRIVIKL REQYENKTIVFNQSSGGDPEIVMLSFNCGGEFFYCNSTKLFNSTWNGTESNNTGDDPIVLPCRIKQVINM WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGNSNETNTTEIFRPGGGNMKDNWRSELYKYKVVRIEPL GIAPTRAKRRVVQREKRAAGLGVMFLGFLGAAGSTMGAASIALTVQARQLLSGIVQQQNNLLRAIEAQQH MLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTTVPWNASWSNKSHDQIWQNMTWMQWEKE IDNYTSLIYNLIEVSQNQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFIVLSI VNRVRQGYSPLSFQTHLPARRGPDRPEGIEEEGGERDRDRSGQLVTGFLAIIWVDLRSLCLFSYHRLRDL LLIVARIVELLGRRGWEILKYWWNLLQYWSQELKSGAVSLLNATAIAVAEGTDRVIEVLQRAGRAILHIP RRIRQGFERALL Protective antigen env Human immunodeficiency virus 1 MN 3342812 CDD:278917 CDD:295533 CDD:197369 11676 ? envelope glycoprotein 8.75 92117.65 938 MN neutralization phenotype variant clone >AAC31819.1 envelope glycoprotein [Human immunodeficiency virus 1] MRVKGIRRNYQHWWGWGTMLLGLLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWAT HACVPTDPNPQEVELVNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNTTNTN NSTDNNNSNSEGTIKGGEMKNCSFNITTSIGDKVQKEYALLYKLDIESIDNDSTSYRLISCNTSVITQAC PKISFEPIPIHYCAPAGFAILKCNDKKFSGKGSCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSE DFTDNAKTIIVHLKESVQINCTRPNYNKRKRIHIGPGRAFYTTKNIKGTIRQAHCIISRAKWNDTLRQIV SKLKEQFKNKTIVFNPSSGGDPEIVMHSFNCGGEFFYCNTSPLFNSTWNGNNTWNNTTGSNNNITLQCKI KQIINMWQKVGKAMYAPPIEGQIRCSSNITGLLLTRDGGIDTDTNDTEIFRPGGGDMRDNWRSELYKYKV VTIEPLGVAPTKAKRRVVQREKRAAIGALFLGFLGAAGSTMGAASVTLTVQARPLLSGIVQQQNNLLRAI ESQQHMLQLTVWGIKQLQARVLAVERYLKDQQLLGFWGCSGKLICTTTVPWNASWSNKSLDDIWNNMTWM QWEREIDNYTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLVGLRIVF AVLSIVNRVRQGYSPLSLQTRPPVPRGPDRPEGIEEEGGERDRDTSGRLVHGFLAIIWVDLRSLFLLSYH HLRDLLLIAARIVELLGRRGWEVLKYWWNLLQYWSQELKSSAVSLLNAAAIAVAEGTDRVIEVLQRAGRA ILHIPTRIRQGLERALL Protective antigen env Simian-Human immunodeficiency virus strain SHIV89.6P 72398919 CDD:278917 57667 ? envelope protein 9.92 40473.44 461 Envelope glycoprotein GP120; pfam00516 >AAZ72871.1 envelope protein, partial [Simian-Human immunodeficiency virus] LNCTNLNITKNTTNPTSSSWGMMEEGEIKNCSFYITTSIRDKVKKEYALFNRLDVVPVENTSYRLISCNT SVITQACPKVSFQPIPIHYCVPAGFAILKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEE DIVIRSENFTNNVKNIIVQLNESVVINCTRPNNNTRERLSIGPGRAFYARRNIIGDIRQAHCNISRAKWN NTLQQIVIKLREKYRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTKGSDII TLQCRIKQIINMWQKVGKAMYAPPIKGQIRCSSNITGLLLTRDGGSSTETEPEIFRPGGGDMRDNWRSEL YKYKVVRIEPIGVAPTRAKRRTVQREKR Protective antigen env Simian-Human immunodeficiency virus strain SHIV-89.6 2828045 CDD:278917 CDD:295533 CDD:197369 57667 ? env 9.04 91775.38 922 Envelope glycoprotein GP120; pfam00516 >AAB99966.1 env [Simian-Human immunodeficiency virus] MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWREATTTLFCASDAKAYDTEVHNVWA THACVPTDPNPQEVVLGNVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLCVTLNCTNLNITKNT TNPTSSSWGMMEKGEIKNCSFYITTSIRNKVKKEYALFNRLDVVPIENTNNTKYRLISCNTSVITQACPK VSFQPIPIHYCVPAGFAMLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENF TDNAKTIIVQLNESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIK LREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQI INMWQKVGKAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIE PIGVAPTRAKRRTVQREKRAVGIGAVFLGFLGAAGSTMGAASVTLTVQARLLLSGIVQQQNNLLRAIEAQ QHMLQLTVWGIKQLQARVLALERYLRDQQLMGIWGCSGKLICTTSVPWNVSWSNKSVDDIWNNMTWMEWE REIDNYTDYIYDLLEKSQTQQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVL SIVNRVRQGYSPLSFQTLLPASRGPDRPEGTEEEGGERDRDRSGPLVNGSLALIWDDLRSLCLFSYHRLR DLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRH IPRRIRQGLERILL Protective antigen env Human immunodeficiency virus 1 155971 9629363 HIV1gp8 AF033819 NP_057856 11676 5770 8340 + Envelope surface glycoprotein gp160, precursor 9.19 91753.45 856 >NC_001802.1:5770-8340 Human immunodeficiency virus 1, complete genome AATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGG ATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGG AAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGC CACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTT AACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAA AGCCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATAC CAATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATG ATACTACCAGCTATAAGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTT TGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTC AATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAA CTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAA TGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACA AGAAAAAGAATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGA GACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAG AGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACG CACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTA ATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAAT AAAACAAATTATAAACATGTGGCAGAAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATT AGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGA TCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA AATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGC TGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGA GGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTG GAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTG CTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGA GTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAA ATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGC TGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACC CCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC GATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCG CTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTC AAATATTGGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGCTCAATG CCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAGCTTGTAGAGCTAT TCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATA >NP_057856.1 Envelope surface glycoprotein gp160, precursor [Human immunodeficiency virus 1] MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI RHIPRRIRQGLERILL Protective antigen env Human immunodeficiency virus 2 1845209 CDD:278917 CDD:278918 CDD:197369 11709 ? envelope polyprotein 8.65 93936.04 945 similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542 >AAB47784.1 envelope polyprotein [Human immunodeficiency virus 2] MEPGRNQLLAVILLTSACLIYCKQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCLPDNDDYQEIPLN VTEAFDAWDNTVTEQAIEDVWRLFETSIKPCVKLTPLCVAMNCNPVTGNNTNATAKPTAARPTTNPSYLT IINESSTCVGADNCTGLGDEGMVNCKFNMTGLEQDKIKGYTDTWYSDDVVCDSTNKTGTNTTCYMRHCNT SVIKESCDKHYWDSMKFRYCTPPGYALLRCNDTNYSGFAPNCPKVVAASCTRMMETQTSTWFGFNGTRAE NRTYIYWHGRDNRTIISLNKHYNLTMHCKRPGNKTVVPITLMSGHRFHSQAVINKKPRQAWCWFKGNWKG AMQEVKQTLAGHPRYKGTNDTSKINFVKPGVGSDPEVTYMWTNCRGEFFYCNMTWFLNWVENRTSQKQRN YAPCHIRQIINTWHKVGQYVYLPPREGELTCNSTVTSIIANIDTDGNQTNITFSAEVAELYRLELGDYKL IEITPIGFAPTSEKRYSSAPARNKRGVFVLGLLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLD IVKRQQELLRLTVWGTKNLQARVTAIEKYLKDQAQLNSWGCTFRQVCHTTVPWVNDSLTPRWNNMTWQEW EKQVRYLEANISQSLEEAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGIIALRIAIYV VQLLSRFRKGYRPVFSSPPGYLQQIHIHTDRGQPANEETEGDAGDASGYDFWPWPINYIQLLIHLLTRLL TGLYSICRDLLSANSPTRRLISQNLTAIRDWLRLKAAYLQYGCEWIQEAFQAIARTARETLAGAWRGLCK AVQRIGRGILAVPRRIRQGAEIALL Protective antigen env Human immunodeficiency virus 1 strain Ba-L subtype B 326367 326371 CDD:278917 CDD:295533 CDD:197369 11676 ? 8.87 91185.73 918 Envelope glycoprotein GP120; pfam00516 >AAA44191.1 env [Human immunodeficiency virus 1] MRVTEIRKSYQHWWRWGIMLLGILMICNAEEKLWVTVYYGVPVWKEATTTLFCASDRKAYDTEVHNVWAT HACVPTDPNPQEVELKNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNATNGN DTNTTSSSRGMVGGGEMKNCSFNITTNIRGKVQKEYALFYKLDIAPIDNNSNNRYRLISCNTSVITQACP KVSFEPIPIHYCAPAGFAILKCKDKKFNGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSAN FADNAKVIIVQLNESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVI KLREQFGNKTIVFKHSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWNVTEESNNTVENNTITLPCRIKQ IINMWQEVGRAMYAPPIRGQIRCSSNITGLLLTRDGGPEDNKTEVFRPGGGDMRDNWRSELYKYKVVKIE PLGVAPTKAKRRVVQREKRAVGIGAVFLGFLGAAGSTMGAAAMTLTVQARLLLSGIVQQQNNLLRAIEAQ QHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKSLNKIWDNMTWIEWD REINNYTSIIYSLIEESQNQQEKNEQELLELDKWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFSVL SIVNRVRQGYSPLSFQTHLPSSRGPDRPGGIEEEGGERDRDRSGPLVNGFLALIWVDLRSLFLFSYHRLR DLLLIVMRIVELLGLAGGWEVLKYWWNLLQYWSQELKNSAVSLLNATAVAVAEGTDRVIEVLQRAVRAIL HIPRRIRQGLERALL Protective antigen env Human immunodeficiency virus 1 strain 96ZM651 13569225 CDD:278917 CDD:197369 11676 ? envelope glycoprotein 8.71 93508.85 949 isolated in 1996 >AAK30970.1 envelope glycoprotein [Human immunodeficiency virus 1] MRVREILRNWQRWWTWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKSYEKEVHNVWAT HACVPTDPNPQEIVLGNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLNCTEVNVTRNVN NSVVNNTTNVNNSMNGDMKNCSFNITTELKDKKKNVYALFYKLDIVSLNETDDSETGNSSKYYRLINCNT SALTQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLAEE GIIIRSENLTNNVKTIIVHLNRSIEIVCVRPNNNTRQSIRIGPGQTFYATGDIIGDIRQAHCNISRTNWT KTLREVRNKLREHFPNKNITFKPSSGGDLEITTHSFNCRGEFFYCNTSGLFSINYTENNTDGTPITLPCR IRQIINMWQEVGRAMYAPPIEGNIACKSDITGLLLVRDGGSTNDSTNNNTEIFRPAGGDMRDNWRSELYK YKVVEIKPLGIAPTEAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASITLTAQARQVLSGIVQQQSNL LRAIEAQQHLLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTAVPWNISWSNKSKTDIWDN MTWMQWDREISNYTNTIYRLLEDSQSQQEQNEKDLLALDSWNNLWNWFDITKWLWYIKIFIMIVGGLIGL RIIFAVLSIVNRVRQGYSPLSFQTLIPNPREPDRPGRIEEEGGEQDKERSVRLVSGFLALAWDDLRSLCL FSYHRLRDFILVTARAVELLRRSSLKGLQRGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDR IIELIQGICRAIRNVPRRIRQGFETALL Protective antigen env Human immunodeficiency virus 1 strain 976 clone 17 475668 CDD:278917 CDD:295533 CDD:197369 11676 ? envelope glycoprotein 8.59 92331.19 944 Envelope glycoprotein GP120; pfam00516 >AAB04093.1 envelope glycoprotein, partial [Human immunodeficiency virus 1] VKETQMNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWKDADTTLFCASDAKAHETEVHNVWATHA CVPTDPNPQEIHLENVTENFNMWKNKMVEQMQEDVISLWDQSLKPCVKLTPLCVTLTCTNATLNCTNLTN GNKTTNVSNIIGNLTDEVRNCSFHMTTELRDKKQKVYALFYKLDIVQINSSEYRLINCNTSVIKQACPKI SFDPIPIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIISSENLT NNAKTIIVHLNKSVEISCTRPSTNTRTSIRIGPGQVFYRTGDITGDIRKAYCEINETKWNEALKQVAGKL KEHFNKTIIFQPPSGGDLEITMHHFNCRGEFFYCDTTQLFNRTWGENETREGRNITLPCKIKQIVNMWQG AGQAMYAPPISGIIKCVSNITGILLTRDGGANNSASETFRPGGGNIKDNWRSELYKYKVVQIEPLGIAPT RAKRRVVEREKRAVGIGAMIFGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLT VWGIKQLQARVLAVERYLKDQKFLGLWGCSGKIICTTAVPWNSTWSNKSYEEIWNNMTWIEWEREISNYT NQIYEILTESQDQQDRNEKDLLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVR QGYSPLSFQIPFHHQREPDRPERIEEGGGEQGRDRSVRLVSGFLALAWDDLRSLCLFLYHRLRDLLLIAT RTVEILGHSSLKGLRRGWEGLKYLGNLLIYWGQELRISAISLLNATAIAVGGWTDRIIEVAQRAWRAILR IPRRIRQGLERSLL Protective antigen env Human immunodeficiency virus 1 VO_0010937 8218033 CDD:278917 CDD:295533 CDD:197369 GOA:Q9IBN3 HSSP:1MEQ InterPro:IPR000328 InterPro:IPR000777 UniProtKB/TrEMBL:Q9IBN3 11676 ? ENV (gp160) 8.84 92355.68 920 HIV-1 GB8 isolated into the cell line JM and the provirus clone was derived by PCR off extracted high molecular weight DNA >gi|8218025:6237-8786 Human immunodeficiency virus type 1 proviral genome, isolate GB8, clone 46R ATGAAAGCGAAGGGGACCAGGAAGAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGT TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGAAGC AACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGACACAGAAAAACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAGGTAGTATTGGGAAATGTGACAGAAAATTTTAACA TGTGGAAAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCC ATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGATACTAATACCGAT AATAGTATAATGGAGGGAGGAGAAATGAAAAACTGCTCTTTCAATATCACCACAAGCATAAGGGATAAGA TGCAGAAAGAATATGCACTTTTGTATAAACTTGATATAGTATCAATAGGTAGTGATAATACTAGCTATAT ATTGACAAAGTGTGACGCCTCAGTCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCAATTCCCATA CATTTTTGTGCCCCGGCTGGTTTTGCGATTCTAAAGTGTAACAATAAGACATTCGATGGAAAAGGACCAT GTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTGTCAACTCAACTGCTGTTAAA TGGCAGTCTAGCAGAAGAAAAGGTAGTAATTAGATCTGACAATTTCATGGACAATACTAAAACCATAATA GTACAGCTGAAAGAAGCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAGGTATATACA TAGGACCAGGGAGAAGATTTTATACAACAGGAAGAATAATAGGAGATATAAGACAAGCACATTGTAACAT TAGTAAAGAAAAATGGAATAATACTTTACACCAGATAGTTATAGAATTGAGGAAACAATTTAGGAATAAA ACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTGTGGAGGGG AATTTTTCTACTGTAAGACAGCACAACTGTTTAATAGTACTTGGAATAGTACTGGAAATGGTACTATAAA GTCAAATACCACTGAAATTATCACACTCCCATGTAGAATAAAACAAATTGTAAACATGTGGCAGGAAGTA GGAAAAGCAATGTATGCCCCTCCCATCACAGGACAAATTAGATGTGCATCACATATTACAGGGCTACTAT TAACAAGAGATGGAGGTAGGGAGAACAATACCAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGATAT GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATGATAGGAGCTATGTTCCTTG GGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCACTGACGCTGACGGTACAGGCCAGACTATT ATTGTCTGGTATAGTGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCGA CTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAAGGATCAAC AGCTCCTAGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTACTGTGCCTTGGAATGTTAGTTG GAGTAATAAATCTCTGGATAAGATTTGGAATAACATGACCTGGATGGAGTGGGAAAGAGAAATTGACAAT TACACAAACACAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAGAATGAACAAGAATTAT TGGAATTGGATAAGTGGGCAAATTTGTGGAATTGGTTTGACATAACAAACTGGCTGTGGTATATAAAAAT ATTCATAATGATAATAGGAGGCTTAATAGGTTTAAGAATAATTTTTGCTGTAATTTCTATAGTGAATAGA GTTAGGCGGGGATACTCACCATTATCATTGCAGACCCACCTCCCAACCCCAAGGGGACCCGACAGGCCCG AAGGAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATCCATCAGATTGGTGAATGGATTCTTAGC GCTTTTCTGGGACGACCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGAGACTTACTCTTGATT GTGACGAGGATTGTGGGACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAGTATTGGTGGAATCTCCTGC AGTATTGGATCCAGGAACTAAAGAATAGTGCTATTAGCTTGCTTAATACCACAGCTATAGCAGTAGCTGA GGGGACAGATAGGGTTATAGAAGTAGTACAAAGAGCTTATAGAGCTATTCTCCACATACCTACAAGAATA AGACAGGGCTTAGAAAGGGCTTTGCAATAA >CAB92793.1 ENV (gp160) [Human immunodeficiency virus 1] MKAKGTRKNYQHLWKWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEKHNVWAT HACVPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNDTNTD NSIMEGGEMKNCSFNITTSIRDKMQKEYALLYKLDIVSIGSDNTSYILTKCDASVITQACPKISFEPIPI HFCAPAGFAILKCNNKTFDGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEKVVIRSDNFMDNTKTII VQLKEAVEINCTRPNNNTRKGIYIGPGRRFYTTGRIIGDIRQAHCNISKEKWNNTLHQIVIELRKQFRNK TIVFNQSSGGDPEIVMHSFNCGGEFFYCKTAQLFNSTWNSTGNGTIKSNTTEIITLPCRIKQIVNMWQEV GKAMYAPPITGQIRCASHITGLLLTRDGGRENNTNETETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAP TKAKRRVVQREKRAVGMIGAMFLGFLGAAGSTMGAASLTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLR LTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTTVPWNVSWSNKSLDKIWNNMTWMEWEREIDN YTNTIYTLIEESQNQQEKNEQELLELDKWANLWNWFDITNWLWYIKIFIMIIGGLIGLRIIFAVISIVNR VRRGYSPLSLQTHLPTPRGPDRPEGIEEEGGEQDRDRSIRLVNGFLALFWDDLRSLCLFSYHRLRDLLLI VTRIVGLLGRRGWEALKYWWNLLQYWIQELKNSAISLLNTTAIAVAEGTDRVIEVVQRAYRAILHIPTRI RQGLERALQ Protective antigen env Human immunodeficiency virus 1 isolate 037 clone 08 487257 CDD:278917 CDD:295533 CDD:197369 11676 ? envelope glycoprotein 8.4 91749 946 Envelope glycoprotein GP120; pfam00516 >AAB05027.1 envelope glycoprotein, partial [Human immunodeficiency virus 1] VMGIERNYPCWWTWGIMILGMIIICNTAENLWVTVYYGVPVWKDAETTLFCASDAKAYDTEVHNVWATHA CVPTDPNPQEIYMENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVQLTPLCVTLDCSYNITNNITNSI TNSSVNMREEIKNCSFNMTTELRDKNRKVYSLFYKLDVVQINNGNNSSNLYRLINCNTSALTQACPKVTF EPIPIRYCAPAGYAILKCNDKEFNGTGLCKNVSTVQCTHGIRPVVSTQLLLNGSLAEGKVMIRSENITNN VKNIIVQLNETVTINCTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSGSQWNRALHQVVGQLRE YWNTTIIFKNSSGGDLEITTHSFNCGGEFFYCNTSGLFNSNWTHNDTASMKPNDTITLPCRIKQIINMWQ RVGQAIYAPPIQGVIRCESNITGLILTRDGGGNINESQIFRPGGGDMRDNWRSELYKYKVVRIEPLGVAP TKAKRRVVEREKRAVVELGAVFIGFLGTAGSTMGAASITLTVQVRKLLSGIVQQQSNLLRAIEAQQHLLK LTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSEREIWENMTWLQWDKEISN YTHIIYELIEESQKQQEKNEQELLELDKWANLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVINR VRQGYSPLSFQTLTPNPRDPDRPGRIEGEGGEQDRGRSIRLVSGFLALAWDDLRNLCLSSYHQLRDFILI VARTVELLGHSSLKGLRLGWEGLKYLGNLLLYWGRELKTSAINLFDTIAIVVAGWTDRVIEVGQRLGRAI LNIPRRIRQGLERALL Protective antigen env from SIV Simian immunodeficiency virus 1490007 9627208 SIVgp6 M58410 NP_054372 11723 6201 8765 ? envelope protein 8.73 91594.7 854 >NC_001549.1:6201-8765 Simian immunodeficiency virus, complete genome TATGGGGAGATTGCTTATAAAAATACTAATAATAGCAATAGGGATAAGTATAGGAATAGGTAACCTGTAT GTGACAGTGTTTTATGGAATCCCAGTATGGAAAAATTCAACAGTTCAGGCATTTTGCATGACGCCCAATA CCAATATGTGGGCAACCACCAACTGCATACCAGATGATCATGATAATACAGAGGTGCCTCTAAACATTAC AGAAGCTTTCGAGGCTTGGGATAATCCGCTGGTAAAACAAGCAGAGAGTAATATACATCTACTCTTTGAA CAAACGATGAGGCCTTGTGTTAAGCTCTCCCCCATATGTATTAAAATGTCCTGTGTAGAGCTGAATGGTA CAGCCACGACAAAGGCCACCACTACTGCAACTACAACAATGACTACCCCCTGTCAGAATTGCAGTACAGA GCAGATAGAAGGAGAAATGGCAGAGGAACCAGCATCCAACTGCACTTTTGCAATTGCAGGATATCAAAGA GATGTAAAAAAGAATTATAGCATGACCTGGTATGATCAGGAGTTAGTCTGCAATAATAAAACAGGAAGTG AAAAGGGAAGTAAGGATTGTTACATGATACATTGTAATGATTCAGTGATAAAAGAAGCTTGTGATAAAAC ATATTGGGATACTTTAAGAGTAAGATACTGTGCACCAGCAGGGTATGCTTTGCTAAAATGTAATGATAAG GATTATAGAGGCTTTGCTCCAAAGTGCAAGAATGTTTCAGTAGTGCATTGTACTAGATTAATCAATACTA CTATAACTACAGGGATAGGATTAAATGGTAGTAGATCAGAAAATAGAACAGAGATATGGCAGAAAGGAGG AAATGATAATGATACAGTTATAATAAAGTTGAATAAGTTTTACAACTTGACAGTGAGATGCCGAAGACCT GGTAATAAAACAGTGTTGCCAGTAACAATCATGGCAGGGTTAGTATTTCACTCTCAGAAATATAATACCA GGTTAAAACAAGCGTGGTGCCACTTCCAAGGAGATTGGAAAGGGGCATGGAAAGAAGTCAGAGAAGAAGT AAAGAAAGTGAAAAATCTTACAGAAGTAAGCATAGAAAATATACATCTGAGAAGGATATGGGGAGATCCA GAATCAGCGAATTTTTGGTTCAATTGTCAAGGTGAATTTTTCTATTGTAAGATGGACTGGTTTATCAATT ATCTAAACAATCGAACAGAAGATGCAGAAGGTACTAATAGGACCTGTGACAAAGGGAAGCCAGGACCAGG ACCATGTGTTCAGAGAACTTATGTTGCCTGCCATATACGACAAGTAGTAAATGATTGGTACACTGTCTCT AAAAAGGTATATGCTCCACCAAGGGAAGGTCATTTGGAGTGTAACTCATCAGTCACGGCACTATACGTGG CAATAGATTATAACAACAAGTCTGGCCCAATAAATGTGACCCTAAGTCCTCAGGTACGCAGCATATGGGC GTACGAACTGGGAGACTATAAATTAGTAGAGATAACACCAATTGGCTTTGCTCCTACAGATGTAAGAAGA TATACTGGCCCCACAAGAGAAAAAAGGGTGCCATTCGTGCTAGGGTTTCTAGGCTTCTTGGGAGCTGCTG GAACTGCAATGGGCGCAGCGGCAACAACGCTGACAGTCCAGTCTCGGCATTTGCTTGCTGGGATATTGCA GCAGCAGAAGAACTTGCTGGCGGCTGTGGAACAGCAACAACAGTTGTTGAAGCTGACCATTTGGGGTGTG AAAAACCTCAATGCCCGCGTCACAGCTCTCGAGAAGTACCTAGAGGATCAGGCACGGCTAAATTCATGGG GATGTGCGTGGAAACAAGTATGTCACACCACAGTGCCATGGAAGTATAATAACACTCCTAAGTGGGACAA TATGACTTGGTTGGAGTGGGAGAGACAAATTAATGCCTTGGAAGGCAACATAACTCAACTATTGGAAGAA GCACAAAATCAGGAATCAAAGAATCTGGATCTGTACCAGAAATTGGATGATTGGTCAGGGTTCTGGTCAT GGTTCTCACTGTCAACTTGGTTAGGCTATGTTAAAATAGGATTTTTAGTGATAGTGATTATTCTAGGATT AAGATTTGCATGGGTATTATGGGGATGTATCAGAAATATTAGGCAGGGATATAATCCTCTCCCCCAGATC CATATCCACAGTTCAGCGGAACGGCCAGACAACGGAGGAGGGCAAGACAGAGGTGGAGAAAGCAGCAGCA GCAAATTGATAAGATTGCAGGAAGAGTCCTCAACACCTTCGAGGATCAACAACTGGTGGCTCAACTTCAA GAGCTGCAGCTTGAGAATAAGGACTTGGTGTTACAACATCTGCCTGACCCTCCTCATATTCATCAGGACA GCAGTGGGATACCTGCAGTATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGG CGAGGGCTGCGAGGGAAGCCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAA CAGTCCAAGAAGAGTGCGGCAAGGCCTTGAAAAAGTCCTGGGGTA >NP_054372.1 envelope protein [Simian immunodeficiency virus] MGRLLIKILIIAIGISIGIGNLYVTVFYGIPVWKNSTVQAFCMTPNTNMWATTNCIPDDHDNTEVPLNIT EAFEAWDNPLVKQAESNIHLLFEQTMRPCVKLSPICIKMSCVELNGTATTKATTTATTTMTTPCQNCSTE QIEGEMAEEPASNCTFAIAGYQRDVKKNYSMTWYDQELVCNNKTGSEKGSKDCYMIHCNDSVIKEACDKT YWDTLRVRYCAPAGYALLKCNDKDYRGFAPKCKNVSVVHCTRLINTTITTGIGLNGSRSENRTEIWQKGG NDNDTVIIKLNKFYNLTVRCRRPGNKTVLPVTIMAGLVFHSQKYNTRLKQAWCHFQGDWKGAWKEVREEV KKVKNLTEVSIENIHLRRIWGDPESANFWFNCQGEFFYCKMDWFINYLNNRTEDAEGTNRTCDKGKPGPG PCVQRTYVACHIRQVVNDWYTVSKKVYAPPREGHLECNSSVTALYVAIDYNNKSGPINVTLSPQVRSIWA YELGDYKLVEITPIGFAPTDVRRYTGPTREKRVPFVLGFLGFLGAAGTAMGAAATTLTVQSRHLLAGILQ QQKNLLAAVEQQQQLLKLTIWGVKNLNARVTALEKYLEDQARLNSWGCAWKQVCHTTVPWKYNNTPKWDN MTWLEWERQINALEGNITQLLEEAQNQESKNLDLYQKLDDWSGFWSWFSLSTWLGYVKIGFLVIVIILGL RFAWVLWGCIRNIRQGYNPLPQIHIHSSAERPDNGGGQDRGGESSSSKLIRLQEESSTPSRINNWWLNFK SCSLRIRTWCYNICLTLLIFIRTAVGYLQYGLQQLQEAATGLAQALARAAREAWGRLGAIVRSAYRAVIN SPRRVRQGLEKVLG Protective antigen gag Human immunodeficiency virus 2 1845205 CDD:249943 CDD:279002 CDD:197667 11709 ? gag polyprotein 9.25 55390.11 591 similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542 >AAB47780.1 gag polyprotein [Human immunodeficiency virus 2] MGARNSVLRGKKADELEKIRLRPGGKKKYRLKHIVWAANELDRFRLAENLLESKEGCQKILTVLDPLVPT GSENLKSLFNTVCVIWCLHAEEKVKDTEEAKKLVQRHLVAETGTAEKMPNTSRPTAPPSGKGGNFPVQQA GGNYVHVPLSPRTLNAWVKLVEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDQQAAMQIIREIINEE AADWDAQHPIPGPLPAGQLRDPRGSDIAGTTSTVDEQIQWMYRQQNPVPVGNIYRRWIQIGLQKCVRMYN PTNVLDVKQGPKESFQSYVDRFYKSLRAEQADPAVKNWMTQTLLVQNANPDCKLVLKGLGMNPTLEEMLT ACQGVGGPGQKARLMAEALKEALTPPPIPFAAAQQRRTIRCWNCGKEGHSAKQCRAPRRQGCWKCGKPGH IMANCPDRQAGFLGMGSRGKKPRNFPVAQAPQGLIPTAPPADPAADLLEKYLQQGRKQREQRERPYKEVT EDLLHLEQGETPRREATEDLLHLNSLFGKDQ Protective antigen gag Simian-Human immunodeficiency virus strain SHIV-89.6 2828037 CDD:249943 CDD:279002 CDD:331526 57667 ? gag 9.12 54236.02 573 gag gene protein p17 (matrix protein); pfam00540 >AAB99958.1 gag [Simian-Human immunodeficiency virus] MGVRNSVLSGKKADELEKIRLRPNGKKKYMLKHVVWAANELDRFGLAESLLENKEGCQKILSVLAPLVPT GSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQQI GGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEE AADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNP TNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLVLKGLGVNPTLEEMLTA CQGVGGPGQKARLMAEALKEALAPVPIPFAAAQQRGPRKPIKCWNCGKEGHSARQCRAPRRQGCWKCGKM DHVMAKCPDRQAGFLGLGPWGKKPRNFPMAQVHQGLMPTAPPEDPAVDLLKNYMQLGKQQREKQRESREK PYKEVTEDLLHLNSLFGGDQ Protective antigen Gag from HIV 1 Human immunodeficiency virus 1 VO_0011263 155030 9629360 HIV1gp2 AF033819 NP_057850 11676 335 1837 + Pr55(Gag) 9.42 53447.94 500 >NC_001802.1:335-1837 Human immunodeficiency virus 1, complete genome GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG GTCACTCTTTGGCAACGACCCCTCGTCACAATA >NP_057850.1 Pr55(Gag) [Human immunodeficiency virus 1] MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG HQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLR SLFGNDPSSQ Protective antigen HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [Ref1301:Bråve et al., 2007]. gag from HIV-1 vector pNL4-3 HIV-1 vector pNL4-3 12831136 CDD:249943 CDD:279002 CDD:331526 CDD:312289 11676 ? gag polyprotein 9.31 54183.8 569 from sequence deposited in GenBank Accession Number M19921 >AAK08483.1 gag polyprotein (plasmid) [HIV-1 vector pNL4-3] MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT GSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAADTGNNSQVSQNYPIVQNLQG QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA EWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPT SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTAC QGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPIDKELYPLASLR SLFGSDPSSQ Protective antigen Gag protein from SIV-mnd 2 Simian immunodeficiency virus SIV-mnd 2 VO_0010949 956108 27311167 Siv2gp1 AF367411 NP_758886 159122 736 2289 + gag protein 8.78 55072.29 517 >NC_004455.1:736-2289 Simian immunodeficiency virus 2 isolate SIVmnd-2, complete genome AATGGGCGCGAGCGCGTCAGGTCTTAGGGGAGAAAAATTGGACGAGCTGGAAAAGATTAGGTTACGGCCC TCCGGAAAAAAGAAATACCAGCTGAAACACATAATATGGGTAAGCAAGGAACTAGACAGATTTGGCCTTC ATGAAAAGCTGTTAGAAAGTAAGGAAGGATGCGAGAAAATTCTTAGCGTACTCTTTCCACTAGTTCCTAC AGGGTCAGAAAATTTAATCTCGCTGTACAACACCTGCTGCTGCGTATGGTGCGTACATGCGAAAGAGAAA GTAACAGATACAGAGGAAGCGAAAGAGAAAGTAAAACAAAAGCTCCATCTAGTGGCCGAAAAGGAAAATG CAGCATCAGAAAAAGAACAAAGAGCAATAGTGACACCTAGTGGCCGCTCAAAAAATTACCCAATACAGAT AATAAATCAGACCCCAGTCCATCAGGGAATTTCACCGCGCACGCTGAATGCGTGGGTAAAATGCATAGAA GAGAAGAAGTTTAGCCCAGAAATAGTGCCCATGTTCATAGCCTTGTCTGAAGGGTGCCTCCCCTATGATC TCAATGGCATGCTCAATGCTATTGGAGACCATCAGGGAGCGCTTCAAATAGTGAAGGATGTCATCAATGA GGAAGCTGCAGACTGGAACTTGAGACACCCACAAGTGGGTCCTATGCCCCAAGGTGTCTTGAGAAACCCA ACGGGCAGTGATATTGCTGGAACAACAAGCTCCATAGAAGAGCAGATAGAATGGACTACAAGGGAGCAAG ATGCAGTAAATGTGGGAGGAATATATAAACAATGGATAGTTTTAGGGCTTCAGAAGTGTGTAAGCATGTA TAATCCAGTAAACATCCTGGACATAAAGCAAGGACCAAAGGAGCCGTTCAAGGACTATGTGGACAGGTTT TACAAAGCTCTGCGGGCGGAGCGGACTGATCCACAAGTCAAAACCTGGATGACACAAACTTTGCTCATCC AGAATGCTAACCCAGATTGTAAATCCATCCTTAAAGGGCTAGGCATGAATCCCTCTTTAGAAGAGATGCC GCTAGCCTGCCAAGGGGTAGGAGGCCCTAAATATAAAGCACAAATGATGGCAGAGGCTATGAAGGAAGCC CAGTCAGCTGTAATGATGCAGAATTCGGGAGGGCCACCGCGGGGCCCCCCGAGACAACCTCCTAGAAACA TCAGATGCCCTAACTGTGGAAAATTTGGTCATGGGCTGAGGGACTGTATAAGCCCTCGAAAAAAGGGATG CTTCAAGTGTGGAGATCTAGGACACATAATGAGAAATTGCCCAAAGATGGTGAATTTTTTAGGGAATACC CCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAACGGCCCCTCCAATGCCAG GGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAACAGCAGAAAGCGGAAAG CAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCAGTTCTCTCTTTGGAACA GACCAACTACAGTA >NP_758886.1 gag protein [Simian immunodeficiency virus SIV-mnd 2] MGASASGLRGEKLDELEKIRLRPSGKKKYQLKHIIWVSKELDRFGLHEKLLESKEGCEKILSVLFPLVPT GSENLISLYNTCCCVWCVHAKEKVTDTEEAKEKVKQKLHLVAEKENAASEKEQRAIVTPSGRSKNYPIQI INQTPVHQGISPRTLNAWVKCIEEKKFSPEIVPMFIALSEGCLPYDLNGMLNAIGDHQGALQIVKDVINE EAADWNLRHPQVGPMPQGVLRNPTGSDIAGTTSSIEEQIEWTTREQDAVNVGGIYKQWIVLGLQKCVSMY NPVNILDIKQGPKEPFKDYVDRFYKALRAERTDPQVKTWMTQTLLIQNANPDCKSILKGLGMNPSLEEMP LACQGVGGPKYKAQMMAEAMKEAQSAVMMQNSGGPPRGPPRQPPRNIRCPNCGKFGHGLRDCISPRKKGC FKCGDLGHIMRNCPKMVNFLGNTPWGSGKPRNFPAMPLTPTAPPMPGMEDPAERMLLDYMKKGQQQKAES KQEKKERGPYEAAYNSLSSLFGTDQLQ Protective antigen A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV [Ref265:Takehisa et al., 2001]. gag-pol Human immunodeficiency virus 1 155348 28872819 HIV1gp1 AF033819 NP_057849 11676 335 4641 + Gag-Pol 9.02 152515.27 1435 Pr160 >NC_001802.1:335-4641 Human immunodeficiency virus 1, complete genome GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG GTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATA CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGG AATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATA GGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCA CTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAGATGGAAAAG GAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAG ACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGT TCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGAT GCATATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACA ATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTATCAATAC ATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGAC AACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGAT GGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACT GTCAATGACATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAA GGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAA GACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATTTA AAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGA GGCAGTGCAAAAAATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATA CAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTG TTAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAATAGAGGAAGA CAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTTATCTAGCTTTGC AGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACC AGATCAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTG GCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCA GGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGT CAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACAC ATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCC AGCAGAAACAGGGCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATA CATACTGACAATGGCAGCAATTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGC AGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCAC AATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAG CAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGAT AATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAG GTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTA >NP_057849.4 Gag-Pol [Human immunodeficiency virus 1] MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG HQMKDCTERQANFLREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQ VTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAI GTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEK EGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGD AYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQY MDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWT VNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSK DLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPI QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRGR QKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYL AWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKC QLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTI HTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH NFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQD NSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED Protective antigen gp120 Human immunodeficiency virus 1 2326505 CDD:278917 GOA:O40515 InterPro:IPR000777 UniProtKB/TrEMBL:O40515 11676 ? 9.81 11668 172 Envelope glycoprotein GP120; pfam00516 >CAA74764.1 gp120, partial [Human immunodeficiency virus 1] NGSLAEGEVVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRKNIHLGRGRSVYATEKIIGNVKQAHCN ISRAKWNDTLKQIVEKLREQFGKNKTIVFNQSSGGDPEI Protective antigen IFNG Macaca mulatta 574282 74136365 EGK_03901 CM001263 NP_001028077 9544 11 65143979 65148219 - interferon-gamma 9.92 18339.63 165 Also known as IFN-gamma >gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA >gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta] MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM AELSPAAKIGKRKRSQMFRGRRASQ Vaximmutor Ifng (Interferon gamma) Mouse 15978 33468859 NM_008337 NP_032363.1 MGI:107656; UniProt:P01580 10090 ? >gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA AGTATACCTTTGCAACC >gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus] MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ LLPESSLRKRKRSRC IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria. Vaximmutor The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes [Ref2101:Wang et al., 2009]. IFNG from Macaca nemestrina IgA Fc fragment Macaca mulatta 664734 90265825 NP_001035039 9544 19 60887587 60904465 + Fc fragment of IgA, receptor for 7.75 30407.11 287 Also known as CD89 >gi|109156886:60887587-60904465 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence GATGGACCCCAAAGAGACCACCCTCCTGTGTCTCGGTGAGTTTCAGAGTAAAAGTGGGTTAGAGGGGAAA ACAGGGAAATCCCAAAATAATCCGGGTGTCTCTTGACAGTATGACTAGGAGATTTTAGTGGCTGCCAAGG AGATTCTGACCTCCTTAGTGGAAAGGCAGTCTTTATCAATATGTCTATAACTTTGTCTCTGCCCAAGTCC AACCTAGCTTGTGGGACTCAAGGGTTAATATTTTTATTAAACCTATAGTGTGTTATCTGGGATTAATGAT GGTTCCAAGGTTCCCATCAAAGACAGACTTAGGGGCTGGAATCTGAAAGGTAAAAATAAAGAATGAGCCT CAAAACTGTGATTGTTGTGGAATGAAAAAATATGATTGAACCCCATATAGAAATATGGTTACTAGTATTT TGTTGAAGATTTTTGCATTTATGTTCAACAAAGACGTTATCCCGAAGTTTTCTGGTTTTGTTGCGTCTCT GCCACGTTTTGTTATCAGGATGATGCTGGCCTCATAGAATGAGTTGGGGAGGAGTCCCTCCTCCTGGATT TTTTCAATAGTTTCAGTAGGAATAATACTAGTTCTTCTTGGCCAGGTGCAGTGGCTCACGCCTATAATCC CAGCACTTTGGGAGGCCAAGGCAGGTGGAACACACGGTCAGGAGATCACATCCTGCCTAACACAGTGAAA CCCCGTCTACTAAAAATACAAAAAAATTAGCCAGATGTGGTGGCGGGCACCTGTAGTCCCAGCTACTCGG GAGGCTGAGGCAGGAGAATGGCATGAACCTGGGAGGCAGAGCTTGCAGTGAGCTGAGATCGCACCACTGC ACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAATACTAGCTCTTCTTTATATATC TAGTGGGACTGAGCTGTGTCTCCATCTGGTACTGGTCTTTTCCTGGTCTATCATTACAGAGGGTGATTTG TCATAAAGATTGGAAATGGAAGCTTGATTTTTCATAAATCTCTCTCTTCCAGTGCTCTGTCTGGGCCAGA GGATTCAGGCACAGGAAGGTAAGTGTCCTGTAAATCTCTCCCAGCCCCTTTAGACTCTCTTGGAAGCTCA GGATAAAGAAATTGAGGAATAGCCTGAAGTACAGATTCTTATTTTAGTCCCCATTCCAGTTGTTTCTGCT GTGCTTCTCTTGCATAATTTCTATCACACTTTGTTATAGCCAAATCCTTCAGACTCATTAATGCTCAGAC CTGGATTTATAGTTAGTCCTTGCCTGTGTTAGACTGCCCATGAAGGATCTGTAATCTACTGAATGCTCAA AACTGCAAGAATGAGGAAATCAGGAGTCATTTGCCCAACATCCTTCCTTATGCTTTGTTTTAGCAACCTA CTTCCTCCTGTCACTTCATTTAAAGGGATACTGCCATAGTCTAATCCTACTGAACATTCTACTATTCTAT AGTACTACTGCAGTACTAAGCATGCAGTAGTCTTAAGAGTACTACTGAATATTCTGCCACCCCAACTACT ACTGCCTTAGCCTCCTAATGGGTGTAAGCCCCATGTCCATCCATGTCTGCTCTCTTCCAGCTCCTTCTAT AGCCTGAATTATTTGTGTGTTGAACAATATTCATTCTTCCTATCCATGAGCATGGAATGTTTTTCCATCT GTTTGTGTCATCTATGATTTCTTTGAGCAGCGTTTTGTAGTTCTCCTTGCAGATATCTTCCACCTCCCTG GTTAGCTGTATTCCTAGGTATTTTATTCTTTTTGTGGTAATTGTGAATGGATTCTGTTCTTGATTTGGCT CTTAGCTGAGACGTTTTTGGTGCATAGGAATGCTACTGATTTTTGTATATTGATTTTGTGTCCTGGAACT TTGTCAGAGTCGTTTATCAGATTAAGAAGTGTTTGGGCAGAGATTGTGGTTTTCTAGGTATAGAATCACA TCATCTGCAAACAGGGATGGTTTGACTTCCTTTCTTCCTATTTGGATGCCTTTCATTTCTTTCTCGCCTG ATTGCTTTGGCTAGGACTTCCAGTACTATGTTGAATAGAAGTAGTGACAGAGGGTATCCATGTCTTGTGT CAGTTTTCAAGGGGAATACTCCCAGCTTTTGCCCATTCAATATTATGTAGGCTGTGAGTTTGTCATAGAT CTTCCTTATTATTTTGAAGTACGTTTCTTCAATGCCTAGTTTGTCGAGGTTTTTTAGCATAAAGGGATGT TGGATTTTATCAAAAGCTCTATTGAGATGATTATATGTGTGTGGCCGGGGGATTGTTCTATGAATCACAT TTAAGATTTGTGTATATTGAATCAACCTTGCATCCCAGAAATAAAGCCTACCTCATGGTGGTGGACTGGC TTTCTGATGTGCTGCTGGATTGTTTGCTAGTATTTTCTTGAGGATTTTTGCATTTATGTTCAACAAGGAT ATTGTCCTGAAGTTTTCTGGTTTTGTTGTGTCTCTGCCATGTTTTTGCATCTATGCGGGTCTCATAGAAT GACTTGGGGAGGCATTCCTCTTCCTGAATTTTCTGGAAAGCTTCAGTAGATATAGTACCAGCTCTTCTCT ATGTATCTGATGGGATTCAGCAGTGAGTTTGTCTGGTACTGGCCTTTTTCTTCTTTTGAAGAGGCCTTTT TATTACTGATTCAATTTTGGAGTTCATTATTGGTCTGGTTCATGGAATCAGTTTGTTCTTGGTTCAATCT CAGAAGGATGTATGTGTCCAGGAATCTCTCCATTTATTCTGGATTTTCTAGTTTGTGTGCACAGAGGTGT TCCTAATATTCTCTGATGATTGTATTTCTGTGGGGTCAGTGGTAATATCCCCTTTGTTGTTTCTAATTGT GTTTATCTGGATCATCTCTCTTTTCTTCTTAATTAGTCTAACTAGTCACCTGTCTTACTAATTTTTTTCA AAAATCCAACTCCTGGATTTGCTGATCTTCTGAATGGTTTTTTGCATCTCAATCTCCTTCTGTTCAGCTC TGGTTTTGGTTATTTCTCGTTTTCTACGAGCTTTGGGGTTGATTTCCTCTTGGTTCTCTCAGTTCCTCTC GTTGTGATGTTAGGTTGTTAATTTGAACTTTTTCTAACTTTTTGACGTGGGAGTTTAGTACTATAAACTT CCCCCTTAACACTGCCTTAGTTGTGTCCCAGAGATTCTGCTGTATTTACCCACAAATTCCAGAACAGACT GTTTAATTTCCATGCATTGTACAGTTTTGAGTGGTTTTCTTAGTATCTATTCCTATTTTTATTCCACTGT GCTCTGAGAATGTGCCTGGTATGATTTCACTATTCTGGATTTGTTAAGGATTGTTGTATGTCTGATTGCA TGATTGACTTTAGAGTATGTGCCACGGGGCAATGAAAACAATGTAGATTCTGTTGTTTTGGGGGTGGAGA GTTCTGTAGATGTCCATCAGGTCCCTTTGGTCCAGTGCTGAGTTCAGGTCCTGAATATCTTTGTTTGCCT CAGTGATCTAACACTGTTGACGAGATGTTAAAGTCCCCCCCTATTATTGTGTGGTTGTCTAAGTCTCTTT GTTGGTCTCTCAGAACACGCTTTATGAATCTGGGTGCTTCTGTGTTAGATGCATGATATTTAGGATAGTT AGGTCTTCATGTTCTGTCTTTATTTTTTTCTTTTTCTTTTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTT TGAGATGGAGTCTCACTCTGTTGCCCAGGCTAGAGTGCAGTGGTGCAATCTCGGCTCACTGCAAGCTTCA CCTCCCGGGTTCACGCCATTCTCCTGCTTCAGCCTCCCGAGTAGCAGGGACTACAGGTGCCTGCCACCAC GCCCGGCTAGTTTTCCAACATGGAAAACTATGTTTTCCATATTGCTTGCTTTCTCCCCATCTCTTTCGGG GACCCCAATGGGTTGCCTATTTGGTCTCTTTACATAATCCCATGTTTCTTAGAGGTTTCAAATTTCATTC ATTCTTTTGTATTCTTTTGTCTTCATTTTTGTCTGACTGAATTAGTTCAGAGAGCCAGTATTCATGCTCT GAGATTCCTTCCTCGTTTTGCTTTATTCTGCCGTTAATACTTGTGATTGCATTATGAAATCTTGCAGTGT GTTTTTCAGCTCTATCAGATCCGTTCGGTTCTTTCAAAATGACCGTTTCTTAGATTAGCCCCTGTGTCAT TTTATCGTAATCTTTCGATTCCTCGCATTGGGTTTCAACTTTCTCCTGAATTTGATGACCTTGATTTCTA CTCATATTCTGAATTCTATTTCTGTCATTTCAGCCACTTCCTCCTGGTAAAGAGCCCTTGCTGGGAAGCT CATGTGGGAATTTGGAGGAAGGAAGACACTTGCTTTTTGAGTCTTGTGCTAATTCTTTCTCATCCGTGTG GGCTAATGTTCTTTTAAGTGTGGTGCAATTGGAGTGTTTTTCTTTTTTCTTTTAACTGTGGTGTAATTTG AGTACAGTCAGTAGACTTCTTTTCTGGGTGGTTTCAGAGGGCTGGGGCTTCGCACAGGGTCTTTACTGAT AGCTAAATTCTTGTCCTTGGTATAACGGGGGGTATATTAGCAAGCATTTTTGGTGTTGAAGTTTGGGCTG CAATCCAGTAAGTGATGCTTAAGCATAATGGCCAGTAGGTCATTCCTCATGACGGCCGCTGTGCTCCCTC TCATGCTCTGAATGTGTGGGCTCCTCTCCCACTCAAGCACTGGCTGCAGATCTGGGCTCCGCACTCCCAG GCTGCCCATCACAGCGCTGGGGTGAGCTCAGGTTTTATGTTCCCTCCGTGGCTTGGGGGCAGCAGGGGAA GGGACCTCAGCAGTGGCTGTGGCAGATGGCCTTTCACTTGTCCCTTGGGACTCCACCCCAGAGAGATGTG GAACCACTATCAGTAGTGTGATGAGCCAAGAGTGGGGCGACTGCGCTGTGGGCCCAAGCTAGGGGCCCTG CCTAGTGATGAGCAGCGGGGACAGGTGGGTCACAGGGGTGACAGACTGGCCTCTTCTCCTTAGGGCAGCT TGCGGGAGGTGTGGTTAAGGCACTCAGAGTCTTTGCTCCTTCCCCAGTCTGAGGGCAGCAAGGCCAGGAC CACCGCAGTGGCAGCCGCAGAGGGGCTGTGAGTTGCCTCTGGGAGCTCCGCCACAGAGAAATGCAGACCC ACAGCTCCCAGGCACGCTCCGCAGAGGGTGGGGCTGCTGTGCTGCGGGCTCAGGCTGGGGTTTGGTGAAG AGCAGGGGGCTGAGGGCTCGCAGGGAGAGGAGACTGAGCTCCTCTCTTACGGTGACTGTGGTGTGCTAGA GGCATGAATGAAGGCTGGGGCTCGGCGGCTCACACCTGTCATCCCAGCACTTTGGGAGGCCGAGGCGGGC GGATCACGAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACA AAAAACTAAGCCGGGCGTGGTGGCAGGTGCTTGTAGTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTACAAA TGCTCAGTAAAAAAAATACTAATAATAAAATAAAATAAAATAAAGCATGAATGAAGCTCCTAGGCTCCTT GTTCTTCCTCAGACCACAGGCAGCAGGGGCAGAATCCTTGCCATGGCGGTGGCAGAGGGGCCGTCAGTTG CCTCTGGGAGCCATTCCCCAGGGAAACACGGAGCCACCACCAGTGAGGATGCTGAGGGTAGGGCAGCTGC TCTGCAGTCCCAAGCTGGGGGCTCTGCCTGGTAAAGTGGGGGTGGGGGCTCACGGGGAAGAGAGACTAGA CTCCTCTCTGTCTGATGGCTGTGGCATAATGACCAGTCCCCAACACGTGAAAAAGAATTGTGGGAACTCA GAAACCCAGTTTGTCCCCACCATGGACTCCTTGCACTGCGTTTCAAATTTCTCCTCAATCTCCATGAGCT TCCCAGCCATCCAGATTCTGAATTCTATGTCCCTCGTTTCATTCATCTCAATCTAGCTAAGAACCAGATT TCCAGGGGACTATCGAGTTGCCAGAGTTCTTGTGTTCCTTTTATTTTTTCCTTTTGTGTGACAAGAGTCT TACTCTGTTACCCAGGCTGGGGTGCGGTGGCGTGATCTCAGCTCACGGCTGCAACTTTCACCTCCCAGGT TCAAGCTATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGATTACAGCTGCGTGCCACCACACACAGCTAA TTTTTGTATGTTTAGTAGAACCCAGGTTTTGTCAGGTTGGTCAGGCTGGTCTTGAACTCTTGACCTCCGG TGATCCGCCCGCCTGGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCCGGCCTTGGTGT CGATTCTTTCTCTTGTGTGAGGGCTGGTGTTCCTTTAACTGTGATGTCAGTTGAATACAGTCACTTAGCT TCATTTCTGGGTGTTTTCAGATGCCAGGACTCTGCACGGAATCTTTATTTGTGGCTGGATTTTTCACTTC GTTGTCTACTGGCAAAATATTTCAGTCTTGTATTTTGACGTGTGATCCAGTAGGTGGCACTTAAAAGGGG CTGGCCAGCATACAGGATCTTAGCCACAAGGCTGTTTTGTAGTTTTGTTTCGTTTTTTGTTTTGTTTTTT GACACAGGGTCTTGCTCTGTCACCCAGGCTGGAGCGCAGTGGCACAGTCTCGGCTCACTGCAGCCTCCAT CTATCAGGCTAAGTGATCCTCCTGCCTCAGCCTCCTAAGTAGCTGGGACTACAAGCACATACCACCATAC CAAGAAAATGTTTGTAATTTTTTTTTTTTTTTTTTTTTAGAGATGGGGTTTCACCATGTCTGCCAGGCTG GTCTCAAACTCCTGGGTTTAAGTGATCTGCCTCCCTTGGCCCCCCAACTCTTGTATTTTGACAAAGTTAG CAGTAGTGCTCTGTGGTTGTGGGGAGGGGTGACTTCCTCACCTGGTCCATTCCTGGGCCTTGGAGGAGCC TCCTACAATCACTAGCTCTGCACCCACCGTTTCCTTTGTTAGGATTGTTCTGCCCACGGGGTTCCTTCAG GCAGTGCATGGTGGGAAGACAGGCTGTATCCTTCCCCAGCCAGCCTACGGAGGGAGGACCACCCCACTCC TCTGCAGACTGATGAAATCACGTGTTTCATTCTTCTGAGTGTTCTGAGAATGAGGGCTCCTCACCGCTCA GTCGCCACCCAAGCTGGTGAGTCCTTCTCAGCAAGGGCGGTTGGAACCACCTGATCTGCCATCTCAGTGC TTCCCAGGGGAACCCAGAGCTGCTGGGGCATGGCAGCTCATGCCTGTAATCTCAGTACTTTGGGAGGCCA AGGCGGGCAGATCACGAAGTCAGGAGATCGAGACCATCCTGGATAACATGGTGGAACCACATTTCTACTA AAAATACAAAAATTATCCAGGCATGTGGCGGGCACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGA GAATTGCTTGAACCCGGGAGGCGGAGTTTGCAGTGGGTCGAGATTGCGCCACTGCACTGCAGCCTGGGCG ACAGAGCGAGACTCTGTCTCGAAAAATAATAACAAAAAAAAATAAAGATGGCAACCACAGACACTGGAGA CGACTAGACGGGGAGGAAGAGAGGGGCTTGAAAAACTAACTGCCTACTGGGTACTACGCTCAGCACCTGG GTGACAGGATCCACCGTACCCCAAACCTCAGCATCATAAATTATTTACATGTTTATTTTTATTTATTTAT TTATTTTAATTGAGACAGAGTCTCACTCTGTGGCCCAGGCTGGAGTGCCATGGCGGGATCTCAGCTCACT GCAAGCTCCGCCTCCTGGGTTCACGCCACTCTCCTGACTCATCCTCCCAAGTAGCTGGGACTACAGTCGC CCACCCCCACGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGAGGTTTCACCATGTTAGCCAAGATGG TCTCGATCTCCTGACCTCGTGTTCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA CCACACCTGGCCTAAATTTTTCTTTAAATAAAGAATGACAGGTTCTTCATACCCTAATTTTCTTCCAGGG AACTTTTCCACGCCTTTCATATCTACCAGGTCAAGTCCTGTGGTTCCCTGGGGTGGGTCTGTGAGAATCC AGTGCCAGGCCATTCCTGACGCTTACCTGATCTGGCTGATGATGCTAAAAAACTCCACGTACGAGAAGAG AGACGAAAAACTGGGGTTTTGGAATGATACTACGCCTGAGTTCGTCATTGACCACATGGACGCGAACAAA GCAGGGCGCTATCAGTGCCGATATAGGATAGGGTTCTCCAGGTTCCGGTACAGTGACACCCTGGAGCTAG TGGTGACAGGTAAGGAAACATCCAGGGTCCACAGCCCTGGTGTGATTTTTTTTCTTATTTTTAATAGAGT ATTTTTCGATAAGTTTTAGATTTACAGAAAAAAGAAAAATTGAGATGACTGCTTCACAGAGTTCTCAGCT ATCTGGCCACTTCCCCCAGAGTTAACATCTGACATTACTATGGCACATTTCTTTTTTTTTTTTTTTTTTA ATTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCT CAGCTCACTGCAAGCTCCGCCTCCCGGGTTTACACCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGAC TACAGGTGCCCGCCACCTCGCCTGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTA GCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAG GCGTGAGCCACCGCGCCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCACACACAC ACACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACACACACACACACACACAG AGGTTACACACACACACAAACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACA CACACACACACACACACACAGAGGTTACACACACACACACACACACAGAGGTTACACACACACACAAACA CACACAGAGGTTACACACACACACACACACAGAGGTTACACACACACACACACACAGAGGTTACACAAAC ACACACACACACAGAGGTTACACACACACACACACAAACACACACACACACACACACACACACACAGGTT TCACTTTGCATTCAGGTGTCATGTATCTTTAGCTTTCTCCCGGCTCTCACAGCTTCTCCGATGTTGCTGG TTTTCCATGGCCTTGTCAGTTTTGAGAGTAGAAGTCCATCACTTTCATTGGCCGGGCGCGGTGGCTCAAG CCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGG CTAACACGGTGAAACCCCGTCTCTACTAAAAAATACAAAAAAACTAGCCGGGCGAGGTGGCGGGCGCCTG TAGTCCCAGCTACTCGGGAGTCTGAGGCAGGAGAATGGCGGGAACCCCGGAGGCGGAGCTTGCAGTGAGC TGAGATCCGGCCACTACACTCCAGCCTGGGCGGCAGAGCCAGACTCCGTCTCAAAAAAAAAAAAAAAAGT CCATCACTTTCAAGGGTACTCCCACTATTGGAAATTGTCCGATGTGTTGCTCATGACTAGACTGAGTTAT GGGTTGTTGAAGACCACAGAAGCAAAGTGCCGTTTCATCTCCTCATAGCAAAGGTTTAAACTGTCCATGG GAATATGACTGTTGATGCTGAACTGGCTGTTGTTGAAAGCCTGGCTGAAGTAGTGACTGTGACCAGGCAC CGAGGCTCACGCCTGTAATCCCAGCGCTTTGAGAGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCA CTTTGGGAGGCCGGGCGCAGTAATCCCAGCGCTTTGAGAGGCCAAGACAGGCGGATCACTTAAGCCCAGG AGACCAGCCGAGGCAACATAGTAAGACCCCATCTGTACAAAAAAAACAAAAAATTAGCTGGGCATGGTGG CACCCACCTGTAGTCTCAGCTACTTGAGAGGCTGAGATGGTAGGATCACTTGAGCCTGGGAGGTCGAGGC TGCAGTGAGCCGCGATTATGCCACTGCCCTCAGCCTGGGCGACGGAGTGAGACCCTCTCTAAAATAAATA AATAAATAAAATTTTAAAAAGAAAAAAGAGGCTGGGCACTGTGGTTCACGCCTGTAATCCCAGCACTTTG GGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGAGATTCAAGACCAGCCTGACCAACATGGTGAAACCTC GTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGGAGGTGCCTGTAATCCCAGCTACTCAGGAGG CTGAGGCAGGAGAATCACTTGAACCTCGGAGGTGGAGGTTGTGGTGAGCCAAGATTGTGCCACTGCACTG CAGCCTCGGTGACAGATCGAGACTCCATCTCAAAACACAATAATAGGCCGGGTGCGGTGGCTCACGCCTG TAATCCCAGCACTTTGGGAGGCCAAGATGGGCAGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGACC AACATGGAGAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGTGCACACCTGTAATC CCAGCTTCTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCAGAGGTTGTAGTGAGCCGAGA TCACACAATTGCTCTCCAGCTTGGGCAACAAGAGCAAAGCTCCGTCTCAAAAAATATATATAATAATAGC AATAATCAGAAGAAGAAAAAAATAAAGGAGAAAAGGTCTTGCTAACAGCTCACTCTTCTCTCTCTTAGGC TTGTATGGCAAACCTTCCCTCTCTGTGGATCGGGGTCCAGTGTTGATGCCGGGAGAGAATATTTCCGTCA CGTGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACA GCACCAAAGTGGGGAACACCCGGCCAACTTCTCTCTGGGTCCTGTGGACCTCAATGTCTCAGGGAGCTAC AGGTGCTACGGCTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCCTGGAGCTTGTGG TCACAGGTAGGTACCTCCCCATCCAGCCCTGTGTCCGGGTTGGCTGTCCAGGCCCTTGTCACTGGGCAGG AATATGAATATGAAGAGGTGCACTGAGAATAATGTGAAGAGAGGCAAAGACTCACCCACTCCAGGACAGT GGAGAAAGAAAGTCTTCCCATCACACTTTCCACCTTCACTTCCTCGCTAGAGTTCTCCAGACAGTGTTCA TTGAAAACTTGTGGTCTATGGAGAAAAGAAGGACTGACTCATTTTATTTTATTTTATTTTCTGTGATGGA GTCTTGTTCTGTCGCCAAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTTCGCCTCCCGGG TTCAAGCAGTTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACCATGCAGAGTTTCACCATGTTGTTCAGG CTGGTCTCGATCTCATGACCTTGTGATCCACCCACCTCAGCTTCCCAAAGTGCTGGAATTACAGGCGTGA GCCACCGTGCCCAGTCAAAAAAGGCTAACTTAGAGTCACAGGTTTATGGGCTATGTTGAGACAGTAGATA CCAGGCTCAACCTTGTCTACCACACCTCTCCTTTCCAGTTGCAGCTGGAAATCCTCGAACTCACCAACCG TACTGGAATTTACCATGAGTAATCAAATGGTCATTCATGGTGACCATTTAGTGACCAAATAGTGAGTGAG GGGTCAAATAGTGACATATTTGGTGACCAAATAGTGAGTGAGAGGTCATAGGAAAGACTTTTAAAACCTC TATCATGAGCCCCATTTTTATTTTATTCATTTATTTATTTTGAGACAGAATCTCGTTCTGTCGCCCAGGC TGGAGTGCAGTGGCACAATCTCTGTTCACACTGCAACCTCCACCTCCCAGGTTGAAGCAATTCTCGTGCG TCGGCCTCCTAAGTAACTGGGACCACAGGCGTGCACCACCGCACCAGGCTACTTTTTGTATTTTTAGTAG AGATGGGGTTTTGCCATGTCGCCCAGGCTAGTCTCAAACTCCTGGCCTCAAGTGATCTGTCTGCCTCAGC CTCACAACGTGCTGGGATTACAGGCGTGAGCCACCACGCCTGGTGGTGAAGACTCTAAAGGCTCTTCTCA GACCAGCCTTTGTCCTGAGGGTCACATGCCCGTGTCCAGTTACCTCTCCAGCATCTTTTCAGGAGTTCCA CGGACTCGCCCCTTCATTATCCAGGGTTGAGCTACAGATATTCTGATTAGGATTCCACCTAGTTCTGGTG GTGGTGTAGAGATATGATTAGATATTTAGTGAAATCACCAAGTGAGGAGAGAATGAAAAGAAAACACAAC TTGCCTGGCCGGGTGTGGTGGCGTGAGCCTGTGGTCCCAGCTACGCAGGAGGCTGAGGCAGGAGAATCGC TTGAACCCAGGAGGCGTTGGTTGCACTGAGCCAAGATTGCGCCATTGCACTCCAGCCTGGGTGACAGAAT GAGACTCCATCTCAAGAAAAAAAAAAAAAAACATGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCA CATTGGGAGGCTGAGACGGGCGGATCACTTGAGGTCGGGAGTTCGAGACCAGCCTGGCCAACATGGTGAA ACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCGGGCGCCTGTAATCCCAGCTACTTG GGAGGCTGAGGCAGGAGAATCGTTTGACCAAGGAGGTGGAGGTAGTAGTGAGCCGAGATCGCGCCACTGC ACTCCAGCCTGGGCGACAGAACAAGACTCCGTCTCCAAAAAAAAAAAAAAAACAACCTGCCCGTAATCAC TCCCTTCCCAGTTTATGGAACTTCCCTGCCTGTGGACACAGTCCTGCTGACTGATCAATGTGGTGCTTGC AAAGTGTGAGCCCATCGAGGAGATGCCTGAGGGAGTCACATTTTGGCAAGCGAATAGGGAAATGGGCTCC CGTTTCAGGGCTCTGGGGTTGGGATGGAATGGAACACACCCGCCAACCATTCATCTCCCCGAATTGTGTC TCCAGACTCCATAAACCGAGATTACACGACGCAGAACTTGATCCGCATGGCCATGGCAGGACTGGTCCTC GTGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATAAGGCGCTGAACAAGGAAGCCTCGGCAG ATGTGGCTGAACCGAGCTGGAGCCACCAGATGTGTCAGCCAGGATGGACCTTTGCACGAACACCAAGTGT CTGCAAGTA >gi|90265825|ref|NP_001035039.1| immunoglobulin alpha Fc receptor precursor [Macaca mulatta] MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWLMMLKNSTYEK RDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGE NISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNA LELVVTDSINRDYTTQNLIRMAMAGLVLVALLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFA RTPSVCK Vaximmutor IgG Fc fragment Macaca mulatta 718859 383873191 EGK_10892 CM001271 NP_001244449 9544 19 55776057 55793029 + 3 6.71 38189.56 365 >gi|109156886:55776057-55793029 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence AGAAGGATATTAAAGAGCACCTGCAGGACCTTTCTAACGGGATGTCGGGGGAAGGGCTTGAAGGAGGATC TAGGGAGGCTTCCATAAGATTTTGATTAACATCCAGCGCTAGGGAAGGTCACAGGGATACAAAAGGGTAG GAGGAGGATCCAGAGACCTGCATGTTGTGGACTTCGAAGGCATCCGGTTCCTTTCCCAGCTTTGTCAAGA ATTCCCTGGGCGGCGGACACCCTCATAATAAAAAAAACGGGAACCACAGGGAAGGGGAATAGAAGAACCA CAAGCGTTTTGAGAAACATACATAGGCTGGGCCTAGGGCCTGGGGTGTGCCCTGCAACTGGGGGGGGTGG GGCTGGATGTTCTTGGAGTCAGGGAGCAGCAGCCTCCCACAGGATGTGAGAGAGGAACTGGGGTCTCCAG TCACGGGAGCCAGGAGCCGGCCAGGGCCGCAGGCAGGAAGGGAGCGAGGCTGAAGGGAACGTGAGCCGAC CAGGCCCCGATTGAGGGAGGAGGGAAGGGCCTGGACCCCTGGGCCTGAGGGAGGAGGGGCTGGGGGTCTG GACAGTGCGTCTGAGGGAGGAGGGGCTGGGGGGGTCTCGACACTGGTTCTGAGGGAGGAGGGGCTGGGGG CCTGGACGCCTGGGACGGAGGGAGGAGGCACTGGGGGTCTGGACACTGGGTCCGAGGGAGGAGGGGCTGG GGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGG CTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTGGGTCAGAGGGTGGA GGGGCTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGG TAGAGGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGCGGCCCGGACTCCTGGGTCCG AGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGTGGCCCGGACTCCTGGG TCCGAGGGAGGAGGAGCTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGAGCTGGGGGCCCGGACTCC TCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGA CTCCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGTTGGGGGCC CGGACTCCTGGGTCCGAGGGAGGAGGGGCTGGGGCCTGAGGGGGACGGAAGGGGCGTGGCCGAGCTCGGG GCCGGGACTCTCAGCCTATCAAGTTTCTGTAATTAATTAACTAACTGAGATCCAGTTCAGGGGTGAAAGT TCTTCAGGTAGGAGGAGGGCATTGTTGTCAGTCTGGACCGAGCCCGCAGAGCCCCTCCTCGGCGTCCTGG TCCCGGCCCCTGCCCCGGTACCCCGGGAGGAAGGGCGGGGCCGGGGGTTTTTCGGGAGGAGTCACGTGCC CCCTCCCGCCCCAGGTCGTCCTCTCAGCATGAGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCCTG CTCTTTCTCCTGCCCGGGAGCCTGGGCGCAGGTGAGGGCCGCTGCGGGCCGGGGCCCTGCTGCAGGCGGG CGGTGGGAGGCGGCCCCAGGCAGGCAGGGGCGAAGCCAGCGGGACCCGAGTTCCCCGCGAGTCCCGGGCG CTGCCTTCTCCGCTCAGTTCACTTTCTCAGCGTCTCCTGCTGGGCCTGAGGCTGAGAACCACCTGTCGCT TCTGTGTCTCTGTTTCCCTCTCTCTCTCTCTGGGTCTCTGTCCTCTCTCTCTCTCTGGGTCTCTGTCCTC TCTCTCTCTCTGGGTCTCTGTCTCTGTCTCCCTCTCTCTCTCTGGGTCTCTGTCCCCTCCCTCTGAATCT TCCCTCTCCATAATAGATTCTTCTCCCTCCCTGGATATCTGTCCCACTGCAATCTAGTTCCCCGCCCATG TTCTCCCTTCAGCTCTGTCTCTGTCTGCAGAAAGTCACCTCTCCCTCCTGTACCACCTCACCGCGGTGTC CTCGCCTGCCCCGGGGACGCCTGCCTTCTGGGTGTCCGGCTGGCTGGGCCCGCAGCAGTACCTGAGCTAC GACAGCCTGAGGGGCCAGGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAAGTGTCCTGGTATTGGG AGAAAGAGACCACAGATCTGAGGATCAAGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGGAAA AGGTGAGATTCGAATCCGGAGGGGCAAGGGGCTGGGTCCATGCTCCTGGGCCCCACTTACATGTGTGTGG GCGCCCCAGGCCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAACTGAGCCCTGACAACACCTCGGTGCC CACCGCCAAGTTCGCCCTGAACGGCGAGGAGTTCATGAATTTCGACCTCAAGCAGGGCACCTGGGGTGGG GACTGGCCCGAGGCCCTGGCTATCAGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGGAGCTCA CCTTCCTGCTATTCTCTTGCCCACACCGGCTGCGGGAGCACCTGGAGAGGGGCCGTGGAAACCTGGAGTG GAAGGGTGAGCCGGATCTGCAGCCACAGGCTGTTCTGTCCTCTCTGCCATCACGCCCACCTGCCTCAGTT CCCCTGTCAGGACCCTCAGTCAGCCTCCCACTGCAGCCCACGCTCTGCCCCCATTCCTCAGGGGTTTTTC TACATTCAGCCCTCCCATGGCTCCCCAGCGCCCCCCAAGACAAACTCTTGGCTTCCTTGCCTTTTTTTGT TGAGACGAAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTGTGATCTCGGCTCACTGTAACCTCC GCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCTAGTAACTGGATTACAGGCATGCATCACCAT GCCTGGCTAATTTTGTATTTTTAGTAGAGGCGGGGTTTCTTCATGCTGGTCAGGCTGGTCTCAAATTCCC AACCGCAGGTGATCCGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCATCGCACCTGG CTGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGATTCTCTGTCACCCCAGGCTGGAGTGTGGT GGCACAATCTCAGCTCACTGCAGCCTGAACCTCCCAGGCTCAAGCAATCCTCCCACGTCAGCCTCCCAAG TAGCTGCGACCACAGCATCGTCACACCTGGCTGACTTTAATTTTTATAGACACAGTGTCTCACTACGTTG CCCAGGCTGGTCTTGAACTCCTAGGCTCAAGCAGTCTTACTGCTTTGGCCTCCTGAATAGCTGAGATTAC AGGTGCATACCACCATAACTGGCTAATTTTTTTTTTAGTTTTCCGCACAGTCTGCCTCCCAGGCTAGTGT GCAGCAGCGTGATCTCAGCTCGCTGCACACTCTGCCTCCTGGGTTTAAGCGATTCTCCTGCTGCAGCCTC ATGAGTAGCTGGCACTACAGGCACATCCACCATCTCTGGCTAATTTTTGTAGTTTTAGTAGAGACAGGGT TTCGTCATGTTAGCTAGGCTGGTCTCAAACTCTTGACCTCAAGTGATCCACTCACCTCAGCCTCCCAAAG TGGTGGGATTACAGGCGTGAGCCACCGCATTTGACCATAACTGGCTAATTTTTAAAATTTGTTGTAGAGA TGGCATCTCGCTGTGCTGCCCAGGCCAGACTCAAACTCCTGGCCTCAAGTGATTCTCCCACTTTGGCCTC TCAGGGTGCTGGGATGACAGGTGTGAACCACTGTGCTTGGCCTTCCTTGCCTTAATGCCCTCGTCAGACC CACGCAGCAGCACTTGTCTCTACACAGCTGTCAGAGTCTAGGCTCCAGCCACCCAACATGAGCAATCTTC TCCCTCTGAGCATTTGTTCATCCAGTTCCCCCGGCCCCTCTCTGTTCCACCCTTCCCCCTCTCTGCATAT ACTCCAGCCCTCCTTATTCTTCAAGGTCGGGGCTGGATATCACTTCCTCTGAGAAGCCTTCTCTCAGCTC TGTAGGGCAGAGTTCACTGTTTCCTCCCCAGCGGCCCCAGATCCCCATTCATTCAGCTGTTGGCCAAGAG CATTTGCACTGCCAGACACCGCTCTGGGACGCCGCTCTGGGCCTTGAGCAAAGAGGGAAGTGACACACGT TCACCCTCTGTGGCTTCCAGGCTGCTGGACAAAGATAGATATCGGCTGGGGATTTGCACAGATGTTCATT CCAAGTGCCACAAAGGAGAAGTTGAGACTTAACCAGGTAGTTTTTCTTTGATCGTCTTCTTTCTTTTTTA AGTAGGGAAAATTTCCTTTTTTTTGAGATGGAGTCTCGCTCTTGTCGCCCAGGCTGGAGTGCAATGGCGC AATCTCGGCTCACTGCAACCTCCGCCTCCCAGCTTCAAGTGATTTCTGCCTCAGCCTCCCGAGTTGCTGG GACTACAGGCACGTACCACCATACCTGGCTAATTTTTGTATTTTTTTTAGTAGAGACAGGGTTTCACCAT GTTGGCCGGGATGGTCTTGATCTCTTGACCTTGTCATCCGCCTGCCTCGGCTTCCCAAAGTGCTGGGATT ACAGACATGAGCCACTGTGCCCGGCCTTTTTTTTTTTTTTTTTTTGAGACAGACTTTTGCATTGTTGCCC AGGCTGCAGTGCAGTGGCACAGTCTTGGCTCACTGCAACCTCCACCTCCCAGGGTCAAGCAATTCTCCTA CCTCAGCCTCCCGAGTAGCTGGGAATACGGGCACGCACCACCCTGCCTGGCTAACTTTTGTATTTTTAGT AGAGACGGGTTTCACCATGCTGGCCAGGCTGGTCTCGAACACCTGATCTCGTGATCCGCCCACCTTGGCC TCCCAAAGTGCTGGGATTATAGGCGTGAGCCACCACACCTGGCCTAAGTAGGGAAAGTTTCAAACCACAC TTAAGTAGACACAATAGTATAAAAAGGACCAGGCATGGTGGCTCATGCCTGTAATCACAGCATTTTGGGA GGCCAAGGCAGGTGGATTGCTTCATCCCAGGAGTTCAAGACCAGCCTGGGCAACATAGCAAGACCTCATC TCTACTAAAAACTCAAAAAATTAGCCTGGCATGGTGGTATGTGCCTCTAGTCCCAGCCACTGGGGAGGCT ATGGTGGGAGGATCACTTGAGCTCAGGAGTTTGAGGCAGTAGTGAACTGTGATTGCAATCCTGCACTCCA GCCCAGACTACAGAGCCAGACCCTGTCTCAAAAAGAAAAAAAATATGATGGCCAGACGCGGTGGCTCATG CCTGAATTCCAACACTTTGGGAGGCTGAGGTGGGCAGATCACTTAACAGGAGTTTGAGATAAGCCTGGCC GACATAGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGTGCGGTGGTGGGCGCTTGTAATC CCAGCTACCCTCCACTTCAAGTGATCCACCCTCCTTGGCCTCCCAAAGTGCAAGAGTCACGGTGCCCGGC CAGAGTGTTTTGTTGATAAGTACTTTAGTATGTAACTCTACTAGGTAAGGGCATGTAAAAAAAATTAATA CCAAAACCATTATCACACCTACGATCAATTAACTGTAACTCCTTAATGGCATCAGATGTCTAGTTTTTGT TCACATTTTCCTGACTGTAAATTTTTTTTTTTTTTTTTTGAGACAGTCTCTTTCTCTGTCACCCAGGCTG GAGTGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCAGGTTTACGCCATTCTCCTGCCTCGG CCTCCTGAGTAGCTGAGACTACAGGCGCCTGTCACCTTGCCCGGCTAGTTTTTTGTATTTTTTTTTTTTT TGTTTGTTTGTTTTTTTTGAGACGGAGTCTGGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCTCA GCTCACTGCAAGCTCTGCCCCCCGGGTTTACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTA CAGGCGCCCGCCGCCTCGCCCGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTCGC CAGGATGGTCTCGATCTCCTGACCTAGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGC TTGAGCCACCGCGCCCGGCCGTTTTTTGTATTTTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAGGA TGGTCTCGATCTCCTGACCTCGTGATCTCCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNGCACACCACCATGCCTGGCTATTTTTTGTATCTTTAATAGAGACAGAGTTTCACCAT GTTGGCCAGGCAGGTTTTGAACTCCCGACCCCAGGTGATCCACCTCCCTCGGCCTCCCAAAGTGTTGGGA TTACAGGCATGAGCCACCGCGCTCAGCCGTATTTTTGTTTTCTTTTTTTTTTTTTGGAGACGGAGTCTCG CTCTCTCGCCCAGGCTGGAGTGCAGGGGTGCCATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAG CGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGCCTGCCACCACGCCTGGCTAATTTTT GTATTTTTAGTAGAGATGGGGTTTCACGTGTTAGCCAGGATGGTCTCGATCTCTTGACTCGTGATCCGCC CTCCTCGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACTGTGCCTGGCCATAATTTTTGTATTTT TAGTAGAGACAAGGTTTCACCATGTTGGTCAGGCTGGTCTTGAACTCCTGACCTCATGATCCGCCTACCT CGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCTACTGTGCCCGGCTGGATTCCAATTTTTTATCAGA TAGGTGTTTTGCAAATATTCCTTACACTCTCTAAGTTGTCTTTTCATTGTTTTAACTGTGCCTTTCAGAA AGAAAAAGTTTTTAACTTCGATAAAATAGTTTATTCTTTTTTTTTTTTTTTTTTAAATCATGGGTTATGC TTTTGGTGTCTTATTTCAGAAGTAAGCACTAAACCCAAAATCAGCTAGATCTTCTCCTGTGTATTTTACG AGTTTTAAAGTTTTGCATTTTATAGTTAGGTCTGTGATTCATTTTGAGGTAATTTGAGTTACTTGTGATC TTGAGTGTCTTTTGATTTACAGGTTTCCCATTTTCTTTTTTTTTTTTCCCCTCGTAATTGTGGTTTGAAG AAAGTCCGTTTATGTCCTATTGAGTTTCCCTCAGACTGGATTTTACCCTTTGCATCCTCTGATGTTGCTG GACATAGTCCTCCTTCTCTTCTTTAAAGGAGCAGCTCGATCTGCAAGCTTGATCAGATTCTGGTTCAGTT TTTATGGCAAGAAAAGTTTCGGCCGGGCGCCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGTGGATC ACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAAAATACAAAA ATTAGCTGGGCGAGGTGGCGGGCGCCTGTAGTCCCAGCTATACTGGAGGCTGAGGCAGGAGAATGGCTTG AACCCAGGAGGCGGAGCTTGCAGTGAGTGGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGGGCGAG ACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAACTTTCTGGGTAGTTGGTGGTTATGTCTGTGTG CATAGGCTGCAAATATCTGCTCGCTTCTGTGCTGTTCTGCGGACCACTGGATTCGGGTGTTACAAAGTTC TCTGTCAGGTTTTCTCCTGATGCTTTTAGCGGACAGCCATGGCCACTGCCTTAATCTTTTTTATTTATTT ATTTATTTATTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGTTGGAGTGCAGTGGTGTGATCTCGGCTC ACTGCAACCTCTGCCTTCCAGGTTCAGGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGG CGCATGCCACTATGCCCGGCTAATTTTTGTATTTTTTTGGTAGAGATGGGGTTTCACCATGTTGGTCAGG CTGGTCTTAAACTCCTGACCTTGTGATCCACCTGCCTCGGCCTCCCAAAATGCTGGGATTACAGGCATCA GGCATGAGCCAGCGCGCCTGGCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGAGGGAGTCTGC CTCTGTCACCAGGCTGGAGTGCAGTGGGCATGATCTCGGTTGACTGCAACCTCCACCCCTCAGGTTCAAG TGATCCTCCTGCCTCAGCCTCCTTAGTCGCTGGAATTACAGGTGCACACTACCACACCCAGCTACTTTTT GTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGATGGATTTCTTTTTTTTTAGAGAGATGGAG TTTCACTCTTATTGCCCAGGCTGTAATACAATGGCATGAACTCGGCTCACTGCAACCTCTGCCTCCTAGA TTCAAGTAATCCTCCTGCCTCAGCCTCCAGGGTAGCTGGGACTACAGGCATGCGCCACCATGCACAGCTA ATTTTTATATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCGAAGCTGGTCTTGAACTCCTGACATCAG GTGATCCGCCTGCCTCAGCCTCGCAGAGTGCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNCACCGCGCCAGCCTTTTTCTTTTTTTTTTTTTTTAGACAGAGTCTTGCTCTGTC GCCCGGGCTGGAATGCAATGGTGCAACCTCTGCCCACTGCAACCTTCGCATTCCGAGTTCAAGTGGTTCT CCTGTCTCAGCCTCCTGAGTAACTGGGACTATAGGCGCCTGCCATCATGCCCAGCTAATTTTATGTATTT TTAGTAGAGATGGGGTTTCACCATATTGGCTAAGCTGGTCTTGAACTCCTCACCTTGTGACCCACCCGCC TCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCTGGCCCCAAGTTTATAAATTTTAAT TTATAAAGCTCAATTTTATCTTTGATTCTGTAGCTTTGTTGTGTATTCTCTTTAAGGAATCTTTCCTCCG AGAAAGGTATTCACCTATGTCTTCTAGAAGCTTAGTTGATGAATAGCTTCCACATTTAGTGATACCATTG ATTTTGAGTTAATTGCCTGTTATGATGAGGGTAGGAGTTGAGGTTCATATGTCCAGCCAGCATCATTTGT TGCTAGACCATCATCCCCTCTCCCTCACTGGACTGCAGGGGAGTGTGTTTTGTGTGTAAGGTGTGGATCT GCTTCTGACCCTCTCCTATTCTGCTGATTATTGGACTTAGTGTCAGTACCTCACTCTTGATTTGATGTAG CTTTTTTTTTTTTTTTTCTTTTTTGAGATGGAGTCGCACTCTGTCGCCCAGGCTGGAGAGTAGTGGTGTG ATCTCGGCTTACTGCAAGCTCCGACTCCCGCGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTG GTACTACAGGCGCCCGCCACCACACCCGGCTCATTTTTTTGTATTTTTAGTAGAGATGGAGTTTCACTGT GTTAGCCAGGATGGTCTTGATCTCCTGACCTCCTGATCCGCCCACCTTGGCCTCCCAAAATGCTGGGATT CCAGGTGTGAGCTACTGCACCCATCCTGAATCTATTTTTATGAGAGACATTGGCCTTAAGTTCTCTTTCT TATAATGTCCTTTGTTGTCAAGATGATGCTGACCTCATAAAATATGCTGGGAGAGTGTTTCCTCTGTTTT ATTGCCTGAAGAGTTTGCGTAGGAGTAGAATCATTTCTACATTGGAAGAATTCACTAATTGATGTCTTCC GGACCTGGAATTTTAGTTTTCGGAAAGTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTATGT CGCCCAGGGGGGGGGGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCGGGTTTTTACCCCAT TCTCCTGCCTCAGCCTCCCGAGTAGCCGGGACTACAGGTGCCCACCACCTCCCCTGGCTAGTTTTTTGTA TTTTTTAGTAAAAACAGAGTTTCACTGTGTTAGCCAGGATGGTCTCGAACTCCTGACCTCGTGATCCGCC CGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAACCACCGCGCCCGGCCAGTTTTCGGAAAGTTT TAAACTATGGATTAAACATTTTATTTATTTATTTTTTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNCAGCTACTCGGGAGGCTGAGGCCGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTG AGATCCGGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAATA CTTACAGGACTGCTGACATTTTAAATTTCCTCTTGTGTCAGTTTAGAAGGTTGTATTTATCAAGAATGTG TTCAGTTCATCTAAATTTTCAAATGTGTTAGTATGGAATTTTTCATAATTATCCTCTATCTTTTTTTTTC CTTTCCCCAAGACGAAATCTCGCTCTGTCACTCAGGCTGGAGTGCAGTGGCACGATCCCAGCTCACTGCA ACCTCTGCCTTCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTGCCCA GCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCACGTTGGCCAGTCTGGTCTCAAACTCCTGACC CCAGGTGATCCACCCACTTTGGCCTCCCAAAGTGTTGGGATTACAGGCGTGAGCCACCATGCCCAGCCCA GGGAGGTGACATCTTGAGGGGACACCTTCAGGGTGGATAGGTTCAGTCTCTGTCACCTGGGAAGCGCCTC CTCTTTTACCACCACATTATCCGGGGTTAGCACATTGCAAACATGGAGGCCTCTTTCTGTCATTACCCAG CCCTGGCCCTGGGAGTGGTGGGCTCGGGGCTTAGACCTGTCTGCCTGGTTTCCTGCAGAGCCCCCCTCCA TGCGCCTGAAGGCCCGACCCGGCAACCCTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTACCC TCCGGAACTGCAACTGCGGTTCCTGCGGAATGGGATGGCCGCTGGCACCGGACAGGGCGACTTCGGCCCC AACAGTGACGGCTCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAGTGGCGATGAGCACCACTACTGCT GCATCGTGCAGCACGCGGGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGGTGAGGCCCCGCCCGGTGGTGA TGCTCCTGGTTTCCCGTTGCCTTGTCTCACTGCTGCGCCGGTCCTTCCTGAGTCTGACCTTCCTCCCCGC TGCTGCCATCTCCTTGAATCTGACTGCCTTGTGCCTCGCGCCTTTCAGTGCCCCCAAAGCCTGATGCCTT GTCCTTCCCAAGGCCGACTGCCTTCCGTCCTGCTGCTTCTGGCCTCACTGAGTCTGAAGAGCTGTTAACC ACCATGGCCAGTCCTCCCTGAGTCTGACCGTCTTCCATCCTGCTGCTGCTGCGGCTGCAGGTCTTCCTGG AATCTGACCATTCGTTGTCTGCTATGCCCGTCCTCACCAAGACTGACCACTTGCTGCCTTGCTACTGCTG GGGCCCATGAGGCTGACTTCCCACTGCTCTGCCTGCCTCTCCCCGCTGCGCCGGGACAGCCCCACCCTGC CGCTGCTGGTCCATTGCCAGTGTGACCACGGCGGCCGCTCGTGCTGTGGCTGGTTCTTACATCCAGCCTG GGGGCACCCTGCCGAGATCGCCCGCCTGGCCTTGCCTCTGTCCATCAGACACTTGGTGCTGGGATCTCCA AGGCTGGGAGGGACTGGGACCCCCCACTGCTGTGTCCTGACTGGGTGGGGGTGGACGGGCTGCTCCACAT CTCACAGCGTTCTCTGGCTGCAGAAACTCCAGCCAAGTCCTCGGTGCTCGTGGTGGGAATCGTCATCGGT GTCTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTGTGGAGAAGGATGAGGAGTGGGCTGCCAG GTGTGGGCAGCGGGAGGAAGAGCCTTGGAGAGAGGGACAGAGACCCCAAGAGAGGGGCACACAGACCTGG GAGGAGAGACCTGGTGTGGGGACAGACCCAAAGAGAGGAGGACAGAGACCAGAGAGAAGTGGAGACAGAA ACCCAGAGACGGGGGAACAGAGGCACAGAGAGAGGGGACAGAGGAAGGGGGAGACAGAGACCCCGAGGAG GGAGGCAAAGATGTAGAAAGAGGGGGGATGGAAAATTGGGAGAAGGGGAGACAGGCCCAGAAGGAAGGGG TTAGAGACTGAGGGAGTGTGTGTGAGACACACACAGAAATGGGGGATGCCAGTCAGACCCAGAGCACCTC AGAGATTCTGATGACCTCCCCCTCTCTCTCCACAGCCCCTTGGATCTCCCTCCGTGGAGATGACACCGGG TCCCTCCTGCCCACCCCGGGGGAGGCCCAGGATGCTGATTCGAAGGATATAAATGTGATCCCAGCCACTG CCTGACCATCTGCCATTCCGACTGCTAAAAGCGAATGTAGTCAGGCCCCTTTCATGCTGTGAGACCTCCT GGAACACTGGCATCTCTGAGCCTCCAGAAGGGGTCCTGGGCCCTGTTGTCCTCCCTCTGGAGCCCCGTCC TGTGGTCTGCCTCAGTTTCCCCTCCTAATACATATGGCTCTTTTCCACCTCGATAATATAACACGAGTTT GGGCCCGAATCAGTGTGTTCTCATCATTTTTCAGGCAGGGGAGGTAAGGGAATAAATCAGGGGACTGAAT GGCCGCTGAGGCTCAGATCTCTCCTACAGGTAA >gi|383873191|ref|NP_001244449.1| Fc fragment of IgG, receptor, transporter, alpha precursor [Macaca mulatta] MRVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYDSLRGQAEP CGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELSPDNTSVPTAKFALNGEEF MNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKAR PGNPGFSVLTCSAFSFYPPELQLRFLRNGMAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHA GLAQPLRVELETPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGSLLPTPGEA QDADSKDINVIPATA Vaximmutor IL4 Macaca mulatta 574281 74136371 EGK_16838 CM001258 NP_001028076 9544 6 129082063 129090398 + interleukin 4 9.44 17265.73 153 >gi|109157119:129082063-129090398 Macaca mulatta chromosome 6, Mmul_051212, whole genome shotgun sequence AATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAACTTTGCCCAC GGACACAACTGCCATATCGCCTTACGGGAGATCATCGAAACTCTGAACAGCCTCACAGAGCAGAAGGTGA GTACCTATCTGGCACCATCTCTCCAGATGTTCTGGTGATGCTGTCAGTATTTCTAGGCCATGAAAACGTT AACAGTTGCTAGAGAAGTTGGAACTGGTGGTTGGTGGCAGCCCGGGGCACACAGCCAGGCTTCCCCTGTC ACTCTTTTTTCTGAGGGTTTGTAGGAAGTTTCCTCAGTTGGAGGGAGTGAGAGATGCTCATCAAGGACTG CTCTGTCCAGTTGGAGGTTAACTCTGTCTCTTGCTCTCTCATTTCTGCCTGGACCAAGACTCTGTGCACC AAGTTGACCATAACGGACATCCTTGCTGCCTCCAAGGTAAGAAGCCGTCCCACGGTCTGTTTTAGCACAT GGGGAGATCCATCCCCAAGTGTCTGAATAAGAAACTTGTCTAATGGAAAACAAGCGGGCCCAAATTAACT CTAAGGTGTTAGATGTTTTCAAAGAACGAGAAGTCTGATTTTTACTCTTAAGTGTGTTTTGGTCTTTCTG GTTTCACTTGATTTAGATGTGTAATAGAAAGCTTACATGCTATAGTCCTGACTCAGATCCTGGTCAAAGA AAAGCCCTCTTGGGTTTTACTTAGCTTTGGCATAGTGCCTGGAACGTAGGAGGCACTCAATAAATGCCTG TTGAATGGGAGAATTTTTCTGGCCCATACATTTCTGAAAAACCAAATACTCTCACAGAAACAGATATTGA GATGACAGGTTGAGGGAGCTTTCATTTTGTCTAAGAGACTTCCTATGGCAACAGAAAAGGTATCACCAGA GCCCCTCCTCTTCCACAGCCTGGCCACCTAACAGCCCTCTGGGTTCCAGGGCTGGCGGTCCAGGGCTCCT CAGCTTGCTCTGGCGGGTCGAATTCCCGTCCAGCTCGGTCCGGAACCATCCTGCTGGGCAGCGTCCAGCA CATCCCTGCTTCCGGTTGCCTGGGCACCTCGCCTCTCTGCCTCCTGTGCTGCCTCACCCCCACCCCTCTA TCTGTAGTGGGAGGAGATAGATTTGACAGCTGATAGTGCATTTTCTCTGACAAACACATGACTACAGCCG TATCAATAGTTTTGTGCATTTCAGTTCCTGTTTTCATGGAAACACACAGCTGAGAATGAAAGCCCCAAAG CCTCAATTTCACAGTGGTCTCCTAACTACTGCTTTCCATGCGAACTAGGGGGATGATTTGGCCAGCAGTG AAGCCCTGTGTGTTGGGCAGGGTCACGCCCTGGCACCCAGGCCATAGAACAGGGCCCATCCTGCTTCATG AGGGAAACTGCTCTTCGGGCCTTTATCTGGACTATCTCATTCATTAAACGTTATCCCAGGAGTTCAATAC AGGATGAGATTCCTGAAGGGTAAATCCACACTTTGTTTTTTTTTTCTTTTGAGATAGGGTCTTGCTCTGT CACCCAGGCTAGAGTGCAGTGGTGCGATTTCAGCTCACAGCAGCCTCCACCTCCCAGGCTCAAGCTAACC TCCCACCTCAGCCTCCCAAGTAACTGGGATGACAGGTCTGCGCCACCACGCCTGGCTAACTTTTGTATTT TTGTTGTAAAGATGGGGTCTTGCCATTTCATTTTGCCCAGGCTTGTCTTGAACTTCTGAGCTCAAGCAAT CCATCCACCTCGGCCTCCCAAAGTGCTGGGATTAGCCACTGCACCTGGACAACAGTTTGTGTGTGTGTGT GTGTGTGTGTGTGTGTGTATACACAAAATTTCTAAGTCCTTCCAACCGAGATGGCTCCTACTAGAAGCCA AGAGTCCACCGGGTTGAGCACTGGGTCTCTGGAGGCCTGTGGCACTGCTGAGAAGGCTCTAACAAAGCCA AGGGAAGGGCCACCTCACTAGAAGTCAGGCCTGGAGGAAGGGTGAGGGTTGAGGGCCTGGAGGTGAGACT GCCTATGGTTTTAGACCCCGCTCTGCCACTGACAGCTGTGTGGCTGGCCTTCGGCACATCTTCACACCTC TCTGCACCTCAGTTTCCACGTGTGAAGATACGAAAGTGATTCTGAAGGTGATTGCAAGGTTGATTGGAAT CCAGTTCTTGAGTTAGTGGAAAGGGTTATTGTGAGATGATATAACCCTGATTAAAAGCAAGGACACGTTG CAGAGAAGCGATGATTCTAAGAAGGAGGTGCCCAGGTTGGAAAGGATCAAACCCTCCAGGATGCTGAGCC TGGGGCTATCCATCTGGGCTGTTTCTGGAAGACCTCCAGGCGCAGGCGAGGACACCACTGCCCTCCCGTC CTTAACTCCCCTCTTCACTCAGTCCTCACTCACCTCCCTCTCACACACACAGACATCTCCTAGAACAATC CCCACTGCCTGCCTTTACTCTTACCTGTCTCATTCGCCTTCCCCGAACTTCATCCTCCTGGAGTTCTCAA TCTCACTCTTCTACTCTTTTCTTCCCCTTGAAGATTCAGCACTGCTTACTTACATGTTAAGATATTTCAG AACAGTGAAATGTTGCTATTTTCAAAAACCTACAAAGGTGGTATGCAGAGGAAAAGGTACTTCTTTGTGT TCCCAAAGAAAACATCTTTCCAAAATCCAGCCTATTGATTTTATTTCTTCGGGGGGAACAAGAATTTTAG TATCTCTAAGTTGGGTAGCATTCTACTCTTGGCAGTTGCTGGAAAGAAGGCACTGATCTAGGTCCTGGGC TTCATAGGTAACACCTGTTGGGGTGTCTATGAAGTCAAGGCTGTCTGAGGAACAGCAAAGTGGGAAGAAG CAAGCTGGCTGGTCGATGAAGGGTTTCTTGGGTGGACAAGTAGATGGAGCTATTTCCTACTTACCAAAGA GAGCTAAAGTTCATAATTCTACAGAGAGTTCCATAATGAACCTCAAATATCTCTGTTTTTTGAAGGAGTT TCTCATATAGAGCACTAGCTGACTACCCTGGGCAGGATGGGAGATAATGAATGCAGTGCCAGTCGGGCTG GATTTGTATGGTCCTCAGTGAGGCTGGTCAAGAACCAAGTCAGAACTCTCACAGAGTCACTGCCACAGAA GAAATCTCCTAAGTGGCTGTTTCCTGACATTCCCGGGAGGGACAGACCTCCTTCTCAGTCACTCCCTAAG CAGTTCTGAACGGTGAGGTCAGCCAGGCTGTCAAAGTGCACTCCCTGAGCCACTGGCAGACACACTCAGC AGCCGGAGCTAGACAGGCAGGTAGAAGGAGTCCAGGGTCACAGCAGGGATGGAGTGTCGCCCCCTCGCTG CGATACCAGAGCAACTAAAACGTAAAGGCCGCACTAAAGCTGCCCTTAGGATGTATTCTTTTAAAGTTTT TCCATTTAATGCAGACTCTTTTCAATTCTTATTTTATCCTTGTTTCCTTTAGAAAGTCCTTTGAAAAATA TCTTTAGAGGATTTTTTCCTATACTATGTGGCCATATATGGGTCAAAATTAAGTTTAATTTCCAGGGTCC AAGCCAGCATTTCAGAAAAATCTCACCAAGGTTTGTGGGAAAAGAAGCAAAGGCTTTTTGGCCTTCTTGA AGCTCACTGTTCCCTCTGCAGCAGCATGCATGTCTGCCCACCTCCAGACACTCAGGTAGCATGTGCTGCC CCCCACCAGCCCCTGTGTCCCCTCCACCTCGACTCGCCCACAAAGCACAGAGAGGTCTGTTTCTTGGCTC CAAGAGCCCAAAAATACTGACACACTCTTGTATTTCCAACTAGAATCAGGAACCAGGAGTGACTCTCAGT CAGTTCATTAAGTAAATGTCTTTCCAACCGCTCTGCCCATGGGATGTCACGCCCCACAGAGGAAAGGGGA AGCTTCCGTAGCCTGGGATTCTGGTGCCTCAATCTGGGTCTAGATCTTCCTGAAAAAAAAACGTTAAAAT ATGAACTGCATTCCTAGAATGTAGCCTATATAAATAAGAGATGAACACAAAGATTTATATAGTTTACTCA CTGCCACTTATTTACAGAAAGAGAAAGCTGCTGTAAATAAGGCAAATTACAATTGTAAAGGGGCCTGACA AATGACAGCACCACTATGCAATACGTTTCTATGCAGCTCTCAAACCCATGTTCTCAAATACCACCGAAGG GCTTAGGAAATGCTTATAGTATATGCAAAGGGTAAAAAAGTTACAAAACAGTATCAACAGTTGATCCCTA TTTTAAAAAGTGTTTTTTAAAGTGTGATGATATTTACCAAAATATTAACAGCAGTAGTTACCTCTGGCTG ATGGGATGAGTGAATGTACTTTTGTTGAATATATAATTACCTTTATAGTAAATACACGTTACCTTGATCA TCAGAAAAAAAAATGTAACCGTAAGAACTTGAAAGCTGCTTGGACAGTGCTGCTGATAGAAATCCCTGAG GATCTTGTCACTGTTCTGATTCAGAGGGTCTGGGTGGGGCAGGGGTGGTCTGAGATTCTGTATTCTAAGA AGCTCCCAGTGATGTCCATGATTCTGGTCATGGACCACACTTTTGAGTAGCAAGGGACCAGAGCATGTCG GGGGAGAGGCTGGGGATAGCTTTATCTCAACTGGATAAAGGAACTAGGCTCAAGCTAAGAACCCTCTCCA AGTTCTGCATCTTTGTTCTTCAGTGAAAAATGAGAGGACAGACCAGTTCAGACCGAGACAAAATCCCTCT CCTGGGTTCCCAATGACTTGTCTCCCTGTGTGTCCATTCCCTTCTCTAAGGTTAAGGGCCCCAGGAAGAG CCATGTGGCCAGACCCTCACAGTTGCCAGCATTTCAGGGAGATTCTCACTCTGCACCATTTGGGGCCAAA AGGCCCCTTACAGAAACTCTGCCCAACGCTCAGCTCAATGGCACCTGCTCCCAGAGCCTCCCCTGATCTC CCAGGACACCTTTCCCCAATCTGTACACTTATCTCTTGCTGCCTGGGGTAATGTCTTAGCTCCTCACTTG GACCATGTGCTGCTCTCCTCTCCCATGGGGAGGACCAAACGGATAGTGCTGCCCAAAGCAGCAGAGTCCA GGCCAAAGGATGTGCCCTCATTTATTCAACAGGCATGCAGGATTTCCAGGGAAAGCTGGATTTTAAAACC TTTGGGAACGAGAGCAGAACCTGACTGAGAGCTCATGTGGGCACTGTCCATAGCAGAATAGCTCATGGGG TATAGAGATACGGACGCGGAACGTGGGCTGTAGCGATAGATAGTCCTGCATTCTAGTCCCCACTGTGCCC TTTCCTTGCGGGGTGGCTTTATTCAGGTACCCTTTCAGCAAAATCCTCCAAGAGAAAAGAAACTGGGGGG TTCTGGGGAGAAGGCTGCTGCGTTTGCAATTGGGAGAGGTTGTTGACAGAGGTTTGTGTCTGTGGCAAGC AGCCTTCCTTCAGTGGAATACTTGAAGACAGGTCTGTAGTTGAGCAAACTCACCTCCATTTGTCCCTCTG GAAAGAAGAAATCAAGAGGAAAAAATCTCTTTCCCATCCTCCAAATGGAGCTGGCACATGGCTATCTATG GCATTTGTCTTTCCAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTC TACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTTCACAGGCACAAGCAGC TGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTGGTAAGCTGCACTGTATT CCTAGCAAGCTGGCAGCATGGCTCCTGGTGGACAGCAGCCTCACTTCTAAACACTCCTCCTTAGGAGCTG CAGCACCCTTGGTCAACCCATTCATTCATTCACTCATTCACTAAGTATTTGTTGAAGTTCCGTAAGTGCT GGGTGCGGTTCTAGGTGCTGAGGACGTGTCACTAAAGACACGCAGGCCAAGTCCCTGTTCTCGTGGGATG TTCTAGTGGGAGAGTCAGAAAAACAAACATGTAAAATGATGCCCAGTAGTGATACGTGCTACAAAGAAAA ACATAGGAATAAAGAATGTAAGGGTCATGGGGGAGGGGGCTGACTTAGGAGCTGGTGACATTATCTGAGC AGATATTTGAATTAAGTGAGGGAGCAGGCCACATGACTAACTGGGGAGAGACCATTCCAGGCAGAAGGAG GAGCTATGCAAAGGCCTTAGGATGGAAATGAACTTCCTGTATTTGAAGACCAGTAGGAAGGCCAGTGTGG CTGGATCACAGTGAGTGAGGGGGAGTTTCTAGGACAGCAGATCACACAAGGCCTTGAGATTCCACCACGA GTATGGCAGGGAACACCTGCAGAGCTCTGGGCAGGGCAAAGACTGTACGATCTGATTTACGTGATTTAAA AGGGTCAGTCTGGCTACTGTGTGGTAAATAGGCTGAAAGGGGGAGGCATAGAAGCAAGATGGCCTGTTGG GAGGCAGTAAACCAGGCTAGAGATGATGGTGGCATGGACAGGATGGGAACAGTGGATAGATTTGGGATAT GACTAAAAATAAAACCAGAAAGATTTGCTGACAGATCAGTTGTAAGGGGTAAGATACAGGGGAGGAAAAG ATGACCTCTTCGTTCCTGCCTAAACCCGTCTGGCGATGGTTGGTACCGTTTATAGAGCGATGGAAGACTG GGGGCAAGGCAGGGCTGGAGGTTAAGCAGAAGATCAAGAGTTCAATTTTGTACGTTGTACATGTAAGGTG GCTGTTGGACAGCCAAGTGAAGATGTTGAGAAGATGGTTAGAAGAGTCTGGAACTTAGAGGAGAGGTCAG AACTTGCAGTACAAAAAGGAGAGTCCTTAGATAGATGCTATTGAAAGTCTGAATGACAGAAAGGGAGAGA TCAAAGGACTGAGCCTGAGATCAACACATGGAGGTCAGGAGAGGAGGATCCAGTAAAGGCGCCTGAGACT CCTCAGACCAGTGAGGCAGGAGAACACTGGAGAGTGGGCGGTATCCCAGGAGGCCAGTGAGGACACTCAC GGAGGGAGGGTCGACTGTTTCAAATGTACTGAAAGGTCAGGTCAGGTAAGGACTGAGAAAGGCCCCTGGG TTTGACTGATGGAGGTCATGGGTGAGGCTGATGTAAATGGAGAAGCAGGAAGGAAAGTCCAGCTGGAGTG GGCTCACCGAGGATGGGGCGGTGAGAGAAGCCAAAGAAGGAACAGTGAGGGCAGAACACTCTTTGAAGGT GTTTAGCTATAAGGCTGCAGAGAAACTGAACCATGGCTGCAGGGCGGTTATGGAGTGAGGGAAGCTCTTT TAAGGTGGGGTGTATACCCAGCATGCTAATGCACCTGGGGGAACGGTCTGGTGGAGTAGGGAGAACTGAA GAGAGGAGAAGGAGGAGGAATCATTAGAGGGCAGAAGTCCTTGTGGCCCAGAGTGGGTGTTATCTAATAT CGAGTGGAGGAATTAATTGGCTTTAGAAGAGAACAAGGACATGTATCCCTTCTTTGGGCCTATCACCTTG TAGACAATGGGATAGGTCATGGGATAGGAACTTGGCACAACACATGTTCTCTTTTAATTCTCTCCATTAT CTTATGAAGCAGGCAAGTAGGCAAACAATTGTCCCGACTTTAAAAATAAACTGAAGCTTTTATAAATTAA GTAGTACGTTCTCAGCAATACAATTAATAAATGGTAGAGCTGAGATTCAAACTGAAGCAGTGGCCTGGGG GTAGCATCTGGAACCCTTCCCACCTTTAGGGCTGCTGTGCTGCAGTGCTGCTGTTTAATGACAGGAGGGC CACATGACTGAATCTCTCTCAGCAGTCCAGGCAGCCATGCAGAAGGCCCAGTAGAGCACGGGCAGGTCTG AGCCAGCACCTTCAAGTTCTACCCTCTGAGCAAGCACCTAGCTGTGACACACCTCTCCAGAGACTGCACT CCCCGCCGCCCTGCCCACCGCAAAAGCAGATAGGTAATGGTATACAGTAACCATTTCTAGAAGTGTAAGT AGTATGCACCCAAAACAGGCAACACCTGCTGGCCTAGTGATAGAGACGACTCCCAGTCAGGCTAGACTGG AGGCCTTGGTTTGGTAAGTGTTCAGGTGGCAAGTACCAGAGTAGGCTTGATCAAGTAGACAGGCAGGCAA GACAAATGCTTACCAATGCAAGCTAATTAAATGCTTCTTTTGTAGAACTCCTGTCCTGTGAAGGAAGCCA GCCAGAGTACGTTGGAAGACTTCTTGGAAAGGCTAAAGACGATCATGAAAGAGAAATATTCAAAGTGTCG GAGCTG >gi|74136371|ref|NP_001028076.1| interleukin-4 precursor [Macaca mulatta] MGLTSQLLPPLFFLLACAGNFAHGHNCHIALREIIETLNSLTEQKTLCTKLTITDILAASKNTTEKETFC RAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEASQSTLEDFLERL KTIMKEKYSKCRS Vaximmutor Nef Human immunodeficiency virus 1 VO_0011261 156110 28872818 HIV1gp9 AF033819 NP_057857 11676 8342 8962 + Nef 6.42 22179.3 206 This particular nucleotide sequence has a premature stop codon in place of a well-conserved tryptophan codon at position 8712-8714 that truncates the HIV1 Nef protein sequence to a 123 amino acids-long N-terminal portion (not shown). >NC_001802.1:8342-8962 Human immunodeficiency virus 1, complete genome GATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTACTGTAAGGGAAAGAATGAGACGAGCT GAGCCAGCAGCAGATAGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGAGCAATCACAAGTAGCA ATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGT CACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAA AAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACA CACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGG ATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGATAGAAGAGGCCAATAAAGGAGAGAACACCAGC TTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACA GCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTG >NP_057857.2 Nef [Human immunodeficiency virus 1] MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPV TPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFG WCYKLVPVEPDKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC Protective antigen Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 × 108 plaque forming units of vv-nef, whereas the intact protein was less protective [Ref1296:Zhang et al., 2009]. nef Human immunodeficiency virus 2 1845210 CDD:249884 11709 ? nef protein 6.88 28422.79 319 similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542 >AAB47785.1 nef protein [Human immunodeficiency virus 2] MGASGSKKLSKQSQGLRERLLRARGGGYVRQCSASGGESSQSQGGSGREQKSPSCEGQQYRQGDYMNTPW RTPAMEGQKESYKQQNMDDVDSDDNDQVGVSVTSRVPLRPMTYKLAVDMSHFIKEKGGLEGMFYSRDRHR ILDLYLEKEEGVIPDWQNYTHGPGVRYPMCFGWLWKLVPVNMSQEAEDDETNCLMHPAQTSRYDDIHGET LVWRFNSMLAYEYKAFTLYPEEFGHKSGLPEKEWKAKLKARGIPYSE Protective antigen Nef SIV Simian immunodeficiency virus 1490008 9627209 SIVgp7 M66437 NP_054373 11723 8599 9270 ? nef protein 6.4 24504.09 223 >gi|9627204:8599-9270 Simian immunodeficiency virus, complete genome TATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGGCGAGGGCTGCGAGGGAAG CCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAACAGTCCAAGAAGAGTGCG GCAAGGCCTTGAAAAAGTCCTGGGGTAAAGGTAAAATGACTCCAGACGGCCGCCGCCTGCAAGAAGGAGA CACCTTTGATGAGTGGGATGATGATGAAGAAGAAGTAGGCTTCCCTGTGCAACCTCGAGTCCCCTTAAGA CAGATGACCTATAAATTAGCAGTGGACTTTTCCCACTTTTTAAAATCAAAGGGGGGACTGGATGGGATAT ATTACTCTGAAAGAAGAGAAAAGATCCTGAATTTGTATGCCTTGAACGAGTGGGGAATAATAGATGATTG GCAAGCTTACTCACCAGGCCCGGGGATAAGGTACCCGAGAGTCTTTGGCTTCTGCTTTAAGCTAGTCCCA GTGGACCTGCATGAGGAGGCACGCAACTGTGAGAGACACTGTCTGATGCATCCAGCACAGATGGGGGAAG ATCCTGATGGAATAGATCATGGAGAAGTCTTGGTCTGGAAGTTTGACCCGAAGTTGGCGGTGGAGTACCG CCCGGACATGTTTAAGGACATGCACGAACATGCAAAGCGCTA >gi|9627209|ref|NP_054373.1| nef protein [Simian immunodeficiency virus] MGSSNSKRQQQGLLKLWRGLRGKPGADWVLLSDPLIGQSSTVQEECGKALKKSWGKGKMTPDGRRLQEGD TFDEWDDDEEEVGFPVQPRVPLRQMTYKLAVDFSHFLKSKGGLDGIYYSERREKILNLYALNEWGIIDDW QAYSPGPGIRYPRVFGFCFKLVPVDLHEEARNCERHCLMHPAQMGEDPDGIDHGEVLVWKFDPKLAVEYR PDMFKDMHEHAKR Other pol Human immunodeficiency virus 1 7021456 CDD:278505 CDD:133149 CDD:238823 CDD:278506 CDD:284283 CDD:284281 CDD:278503 CDD:259998 CDD:280240 CDD:279057 11676 ? pol 7.77 90126.73 918 long-term nonprogressor >AAF35355.1 pol, partial [Human immunodeficiency virus 1] FFREDLAFPQGKAREFPSEQTRAISPARRELQVWGRDNNSLSEAGANRQGTVSFSFPQITLWQRPLVAIK IGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVAIEICGHKAIGTVLIGPTPVNI IGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFR KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI GQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLN WASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVAIESIVIWGKTPKFKLPIQKETWEAWWTEY WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQ KTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGN EQVDKLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMAGDFNLPPVVAKEIVACCDKCQLKGEAMHGQVD CSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSNT VKAACW Protective antigen pol Simian-Human immunodeficiency virus strain SHIV-89.6 2828038 CDD:133149 CDD:295487 CDD:278506 CDD:238185 CDD:284283 CDD:284281 CDD:278503 CDD:259998 CDD:280240 CDD:279057 CDD:278951 57667 ? pol 7.9 113326.45 1139 Retropepsins, pepsin-like aspartate proteases; cd05482 >AAB99959.1 pol, partial [Simian-Human immunodeficiency virus] LELWERGTLCKAMQSPKKTGMLEMWKNGPCYGQMPRQTGGFFRPWSMGKEAPQFPHGSSASGADANCSPR GPSCGSAKELHAVGQAAERKAERKQREALQGGDRGFAAPQFSLWRRPVVTAHIEGQPVEVLLDTGADDSI VTGIELGPHYTPKIVGGIGGFINTKEYKNVEIEVLGKRIKGTIMTGDTPINIFGRNLLTALGMSLNFPIA KVEPVKVALKPGKDGPKLKQWPLSKEKIVALREICEKMEKDGQLEEAPPTNPYNTPTFAIKKKDKNKWRM LIDFRELNRVTQDFTEVQLGIPHPAGLAKRKRITVLDIGDAYFSIPLDEEFRQYTAFTLPSVNNAEPGKR YIYKVLPQGWKGSPAIFQYTMRHVLEPFRKANPDVTLVQYMDDILIASDRTDLEHDRVVLQSKELLNSIG FSTPEEKFQKDPPFQWMGYELWPTKWKLQKIELPQRETWTVNDIQKLVGVLNWAAQIYPGIKTKHLCRLI RGKMTLTEEVQWTEMAEAEYEENKIILSQEQEGCYYQEGKPLEATVIKSQDNQWSYKIHQEDKILKVGKF AKIKNTHTNGVRLLAHVIQKIGKEAIVIWGQVPKFHLPVEKDVWEQWWTDYWQVTWIPEWDFISTPPLVR LVFNLVKDPIEGEETYYTDGSCNKQSKEGKAGYITDRGKDKVKVLEQTTNQQAELEAFLMALTDSGPKAN IIVDSQYVMGIITGCPTESESRLVNQIIEEMIKKSEIYVAWVPAHKGIGGNQEIDHLVSQGIRQVLFLEK IEPAQEEHDKYHSNVKELVFKFGLPRIVARQIVDTCDKCHQKGEAIHGQANSDLGTWQMDCTHLEGKIII VAVHVASGFIEAEVIPQETGRQTALFLLKLAGRWPITHLHTDNGANFASQEVKMVAWWAGIEHTFGVPYN PQSQGVVEAMNHHLKNQIDRIREQANSVETIVLMAVHCMNFKRRGGIGDMTPAERLINMITTEQEIQFQQ SKNSKFKNFRVYYREGRDQLWKGPGELLWKGEGAVILKVGTDIKVVPRRKAKIIKDYGGGKEVDSSSHME DTGEAREVA Protective antigen Pol SIV Simian immunodeficiency virus SIV-mnd 2 956107 27311168 Siv2gp2 AF367411 NP_758887 159122 2049 5081 + pol protein 7.91 106929.88 1010 >gi|27311166:2049-5081 Simian immunodeficiency virus SIV-mnd 2, complete genome ATTTTTTAGGGAATACCCCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAAC GGCCCCTCCAATGCCAGGGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAA CAGCAGAAAGCGGAAAGCAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCA GTTCTCTCTTTGGAACAGACCAACTACAGTAGTAGAGATAGAAGGGCAAAAAGTGGAGGCCTTACTGGAC ACAGGAGCTGATGATACAGTAATCAAAGATCTAGATTTAAAAGGTAATTGGAAACCACAGATTATTGGAG GAATTGGAGGATCAATCAATGTAAAACAGTTTTTCAATTGTAAAGTAACAATAGCAGGCAAAACTACACA CGCTTCAGTCCTAGTGGGCCCCACACCTGTAAATATTGTAGGTAGAAATGTGCTGAAGAAATTAGGATGT ACACTAAATTTTCCAGTTAGTAAAGTAGAAACAGTAAAGGTAACACTAAAACCAGGAACTGACGGACCTA AAATAAAACAATGGCCATTGTCTAAGGAAAAGATTTTAGCCTTACAAGAAATATGTAGTCAAATGGAGAA GGAAGGCCAGATCTCTAAGATAGGTCCAGAAAATCCTTACAACACACCGGTGTTTTGCATCAAAAAGAAA GATGGAACCAGCTGGAGAAAATTGGTAGATTTTAGACAGTTAAACAAAGTAACTCAGGACTTCTTTGAGG TGCAGTTGGGAATCCCACACCCTGGAGGTCTCAAACAATGTGAGCAAATTACAGTACTGGACATAGGGGA TGCCTATTTCTCATGTCCTTTGGATGAGGACTTTAGAAAGTACACTGCATTCACCATTCCATCGGTGAAT AATCAGGGCCCAGGAATCAGGTACCAGTATAATGTCCTACCACAGGGATGGAAGGGCTCCCCAGCCATTT TCCAGGCAACAGCAGATAAAATCTTACAGCCCTTCAGAGAGAGACATCCAGATGTAGTGATCTATCAATA TATGGATGATCTCTTTGTTGGGAGTGATAGAGTTGCCCCAGAACACAGCAGAATGATTCAAGAGTTAAGA GACCACCTCTTGTTTTGGGGGCTCGAGACCCCAGACAAGAAGTTTCAAAAGGAACCACCCTTTGAGTGGA TGGGATACATACTGCACCCTAAGAAATGGACAGTGCAGAAAGTACAGCTTCCAGAGAAAGAAGAATGGAC AGTAAATGACATCCAAAAGTTGGTAGGGAAACTTAATTGGGCAAGTCAGATTTATTCCGGAATTAAAACA AAAGAGCTCTGTAGACTAATTAGAGGGGCAAAACCCCTAGATGAAAAAGTAGAATGGACTAGAGAAGCAG AATTAGAATATGAAGAAAACAAACTCATAGTGCAGGAGGAAGTGCATGGAGTATACTATCAACCAGAGAA GCCTTTAATGGCAAAGGTTCAAAAATTGACACAAGGGCAATGGAGTTACCAAATAGAGCAGGAGGATAAT AAGCCGCTGAAGGTAGGGAAATATGCCAGAACAAAGAATGCTCATACAAATGAGCTTAGAGTGCTTGCAG GACTAGTACAGAAGATTGCAAAAGAAGCTTTAGTGATCTGGGGAAAACTCCCTAAGTTTTATCTGCCAAT AGAAAGAGAAGTCTGGGACCAGTGGTGGCCAGAATATTGGCAAGCCACATGGATTCCCGAATGGGAATTT GTATCCACTCCACACCTTATCGGGTTGTGGTATAACCTGTTGAGAGAACCTGTGCCAGGAGAAGATGTGT ATTATGTGGATGGAGCAGCTAACAGAAACTCCAAAGAAGGGAAAGCAGGATATGTAACAGCTAGAAATAA ATCCAGAGTAATAGCCCTAGAGAATACCACAAACCAAAAAGCAGAATTGGAGGCAATAAAAATGGCATTA CAAGACTCAGGACCAAAAGTAAATATAGTGACAGATTCACAGTATGCTATGGGTATCCTATCGGCAGCAC CCGACCAATCAGACAACCCCATAGTAAGAGAAATTATAGAACTCATGATCCACAAGGAAGCAGTATACCT AGCTTGGGTACCAGCACACAAAGGCATAGGAGGGAATGAGCAAGTAGATAAACTAGTGAGCAGAGGAGTA AGGCAAGTACTGTTTTTAGAAGGCATAGATAAAGCACAAGAAGAGCATGATAAATATCACAATAATTGGA GGGCATTAGCACAAGACTTCTGTATACCAAACATAGTGGCAAAAGAAATAGTAGCCCAGTGTCCAAAGTG TCAAACAAAAGGAGAGCCAATACATGGCCAGGTAGATACATCCCCAGGAACCTGGCAAATGGACTGCACA CATATGGAAGGAAAAGTAATCATAGCAGCAGTCCATGTAGCAAGTAGGTATCTAGAAGCAGAAGTAATAC CCACAGAAACAGGAAAAGAAACAGCACACTTCCTGTTAAAATTAGCAGGTAGATGGCCAGTAAAACATCT ACACACAGATAATGGCCCTAATTTCACCAGTGAAAAAGTAGCCACAGTCTGTTGGTGGGCTCAAATAGAG CACACTACAGGAATTCCCTACAATCCTCAGAGTCAAGGAGTAATAGAGGCAAAAAACCATCATCTCAAAC AAATCATAGGGCAAGTTAGAGACCAAGCAGAGAAACTAGAAACAGCAGTTCAAATGGCAGTATTAATTCA CAATTTTAAAAGAAAAGGGGGGATAGGGGAATACAGTCCAGGAGAAAGAATAGTAGACATTATAGCAACA GACCTCCTAACAACTAAATTACAACACAATATTCAAAAAATTCAAAATTTTCGGGTTTATTACAGAGAAG GAAGGGACCAACAGTGGAAAGGACCAGCAGAACTCATTTGGAAAGGAGAAGGAGCGGTGGTAATCAAAGA GGGGACAGACTTGAAGGTAGTACCAAGGAGAAAAGCAAAAATCATCAGAGATTATGGAAAAACAGTGGAT AGTGATCCCAACGTGGAAGCTTG >gi|27311168|ref|NP_758887.1| pol protein [Simian immunodeficiency virus SIV-mnd 2] FFREYPLGQWQTQELPGDAIDPNGPSNARDGRPSRENAVRLHEERATAESGKQTGKEREGSIRGSLQLPQ FSLWNRPTTVVEIEGQKVEALLDTGADDTVIKDLDLKGNWKPQIIGGIGGSINVKQFFNCKVTIAGKTTH ASVLVGPTPVNIVGRNVLKKLGCTLNFPVSKVETVKVTLKPGTDGPKIKQWPLSKEKILALQEICSQMEK EGQISKIGPENPYNTPVFCIKKKDGTSWRKLVDFRQLNKVTQDFFEVQLGIPHPGGLKQCEQITVLDIGD AYFSCPLDEDFRKYTAFTIPSVNNQGPGIRYQYNVLPQGWKGSPAIFQATADKILQPFRERHPDVVIYQY MDDLFVGSDRVAPEHSRMIQELRDHLLFWGLETPDKKFQKEPPFEWMGYILHPKKWTVQKVQLPEKEEWT VNDIQKLVGKLNWASQIYSGIKTKELCRLIRGAKPLDEKVEWTREAELEYEENKLIVQEEVHGVYYQPEK PLMAKVQKLTQGQWSYQIEQEDNKPLKVGKYARTKNAHTNELRVLAGLVQKIAKEALVIWGKLPKFYLPI EREVWDQWWPEYWQATWIPEWEFVSTPHLIGLWYNLLREPVPGEDVYYVDGAANRNSKEGKAGYVTARNK SRVIALENTTNQKAELEAIKMALQDSGPKVNIVTDSQYAMGILSAAPDQSDNPIVREIIELMIHKEAVYL AWVPAHKGIGGNEQVDKLVSRGVRQVLFLEGIDKAQEEHDKYHNNWRALAQDFCIPNIVAKEIVAQCPKC QTKGEPIHGQVDTSPGTWQMDCTHMEGKVIIAAVHVASRYLEAEVIPTETGKETAHFLLKLAGRWPVKHL HTDNGPNFTSEKVATVCWWAQIEHTTGIPYNPQSQGVIEAKNHHLKQIIGQVRDQAEKLETAVQMAVLIH NFKRKGGIGEYSPGERIVDIIATDLLTTKLQHNIQKIQNFRVYYREGRDQQWKGPAELIWKGEGAVVIKE GTDLKVVPRRKAKIIRDYGKTVDSDPNVEA Other rev Simian-Human immunodeficiency virus strain SHIV-89.6 2828043 CDD:278833 57667 ? rev 9.94 12952.65 173 REV protein (anti-repression trans-activator protein); pfam00424 >AAB99964.1 rev [Simian-Human immunodeficiency virus] MAGRSGDSDEELIRTVRLIKLLYQSNPPPSLEGTRQARRNRRRRWRERQRQIRSISERILGTYLGRSAEP VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE Protective antigen rev from HIV 1 Human immunodeficiency virus 1 155908 9629359 HIV1gp6 AF033819 NP_057854 11676 5515 8198 + Rev 9.36 12578.23 116 >NC_001802.1:5515-8198 Human immunodeficiency virus 1, complete genome TATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTAT CAAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAAT AATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATA GACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAG CACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAG AAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGC ATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGAC CCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAG AACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACT CTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATA ATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAG AATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAG TTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGT GCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATG TCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCT AGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTG AACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAG GACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAG AGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACA ATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAAT TTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTC AAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAG AAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGC TGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATAT GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGT TCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATT GTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTC ACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGC TCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAG TAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTAC ACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGG AATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATT CATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTT AGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAG GAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTGGCACT TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTA ACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGT ATTGGAGTCAGGAACTAAAGAATA >NP_057854.1 Rev [Human immunodeficiency virus 1] MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEP VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE Protective antigen rev MN isolate Human immunodeficiency virus 1 MN 3511264 CDD:189539 11676 ? rev protein 116 neutralization phenotype variant molecular clone >gi|3511264|gb|AAC33786.1| rev protein [Human immunodeficiency virus 1] MAGRNGDSDEELLKTVRLIKFLHQSNPPPSSEGTRQARRNRRRRWRERQRHIRSISAWILSNYLGRPAEP VPPQLPPLERLTLDCSEDCGTSGTQGVGSPQILVESPTVLESGTKE Other tat Human immunodeficiency virus 2 1845211 CDD:278940 11709 ? tat protein 9.61 14481.48 190 similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542 >AAB47786.1 tat protein [Human immunodeficiency virus 2] METPLKAPESSLKSYNEPSPCTSEWEVAAQELAKQGEELLAQLHRPLEACTNPCYCKKCSFHCQLCFLKK GLGIWYVRKGGRRRTPKRTKTHPPSTPDKSISIQTGDSRPTKKQKETPETPVATTSGLGR Protective antigen Tat Human immunodeficiency virus 1 VO_0011262 155871 9629358 HIV1gp5 AF033819 NP_057853 11676 5376 7969 + Tat 10.43 9638.3 86 the length of Tat varies depending on virus strain or clade >NC_001802.1:5376-7969 Human immunodeficiency virus 1, complete genome AATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACC AATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCT ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATC AAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATA ATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAG ACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGC ACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAGA AAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCA TCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACC CCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGA ACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTC TGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATAA TGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAGA ATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAGT TGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTG CCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATGT CAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCTA GCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTGA ACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGG ACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGA GCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAA TAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAATT TTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCA AATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGA AAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCT GCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATG AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTT CTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTG TCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCA CAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCT CCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT AATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGA ATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTC ATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTA GGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGG AATA >NP_057853.1 Tat [Human immunodeficiency virus 1] MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS KQPTSQPRGDPTGPKE Protective antigen HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [Ref1301:Bråve et al., 2007]. tat Simian-Human immunodeficiency virus strain SHIV-89.6 2828042 CDD:278940 57667 ? tat 10.4 11598.34 158 Transactivating regulatory protein (Tat); pfam00539 >AAB99963.1 tat [Simian-Human immunodeficiency virus] MEPVDPRLEPWKHPGSKPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS KQPSSQPRGDPTGPKEQKKKVERETETDPVH Protective antigen vif Simian-Human immunodeficiency virus strain SHIV-89.6 2828039 CDD:278957 57667 ? vif 10.5 24244.15 273 Retroviral Vif (Viral infectivity) protein; pfam00559 >AAB99960.1 vif [Simian-Human immunodeficiency virus] MEEEKRWIAVPTWRIPERLERWHSLIKYLKYKTKDLQKVCYVPHFKVGWAWWTCSRVIFPLQEGSHLEVQ GYWHLTPEKGWLSTYAVRITWYSKNFWTDVTPNYADILLHSTYFPCFTAGEVRRAIRGEQLLSCCRFPRA HKYQVPSLQYLALKVVSDVRSQGENPTWKQWRRDNRRGLRMAKQNSRGDKQRGGKPPTKGANFPGLAKVL GILA Protective antigen vpr Simian-Human immunodeficiency virus strain SHIV-89.6 2828041 CDD:278923 57667 ? vpr 5.91 11514.23 158 VPR/VPX protein; pfam00522 >AAB99962.1 vpr [Simian-Human immunodeficiency virus] MEERPPENEGPQREPWDEWVVEVLEELKEEALKHFDPRLLTALGNHIYNRHGDTLEGAGELIRILQRALF MHFRGGCIHSRIGQPGGGNPLSAIPPSRSML Protective antigen vpu Simian-Human immunodeficiency virus strain SHIV-89.6 2828044 CDD:109608 57667 ? vpu 4.6 8647.38 138 Vpu protein; pfam00558 >AAB99965.1 vpu [Simian-Human immunodeficiency virus] MQPIQIAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEM GHHAPWDVDDL Protective antigen vpu Human immunodeficiency virus 1 155945 9629366 HIV1gp7 AF033819 NP_057855 11676 5607 5855 + Vpu 4.43 8250.01 82 Vpu and gp160 are translated from different reading frames of the same bicistronic mRNA >gi|9629357:5607-5855 Human immunodeficiency virus 1, complete genome AATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGG TCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAA TAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGA GATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTA >gi|9629366|ref|NP_057855.1| Vpu [Human immunodeficiency virus 1] MQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVE MGHHAPWDVDDL Other Aggarwal et al., 2005 journal Aggarwal P, Kumar S, Vajpayee M, Seth P 2005 18 4 649-656 Viral immunology Ami et al., 2005 journal Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M 2005 79 20 12871-12879 Journal of virology Ara et al., 2001 journal Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K 2001 103 1 98-9105 Immunology Ayyavoo et al., 2002 journal Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB 2002 Jan 14 1 13-22 International immunology Bagley et al., 2003 journal Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM 2003 21 23 3335-3341 Vaccine Barouch et al., 2012 journal Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP 2012 109 22 8694-8698 Proceedings of the National Academy of Sciences of the United States of America Barrett et al., 1989 journal Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F 1989 5 2 159-171 AIDS research and human retroviruses Benson et al., 1998 journal Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G 1998 72 5 4170-4182 Journal of virology Bielinska et al., 2008 journal Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr 2008 24 2 271-281 AIDS research and human retroviruses Bomford et al., 1992 journal Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T 1992 8 10 1765-1771 AIDS research and human retroviruses Bower et al., 2004 journal Bower JF, Yang X, Sodroski J, Ross TM 2004 78 9 4710-4719 Journal of virology Boyer et al., 1997 journal Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB 1997 3 5 526-532 Nature medicine Bråve et al., 2007 journal Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E 2007 25 39-40 6882-6890 Vaccine BrÃ¥ve et al., 2005 journal BrÃ¥ve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B 2005 12 6 1197-1205 Molecular therapy : the journal of the American Society of Gene Therapy Breton et al., 2007 journal Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B 2007 88 Pt 1 217-225 The Journal of general virology Buchbinder et al., 1994 journal Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD 1994 Aug 8 8 1123-8 AIDS (London, England) Calarota et al., 1998 journal Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandström E, Wahren B 1998 351 9112 1320-1325 Lancet Calarota et al., 2008 journal Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J 2008 26 40 5188-5195 Vaccine Caley et al., 1999 journal Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE 1999 Aug 6 17 23-24 3124-35 Vaccine Caputo et al., 2003 journal Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B 2003 21 11-12 1103-1111 Vaccine Casimiro et al., 2003 journal Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW 2003 77 11 6305-6313 Journal of virology Chan et al., 1997 journal Chan DC, Fass D, Berger JM, Kim PS 1997 Apr 18 89 2 263-73 Cell Chen et al., 2005 journal Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P 2005 May 79 9 5537-47 Journal of virology Chin'ombe et al., 2009 journal Chin'ombe N, Bourn WR, Williamson AL, Shephard EG 2009 6 87 Virology journal Coakley et al., 2005 journal Coakley E, Petropoulos CJ, Whitcomb JM 2005 Feb 18 1 9-15 Current opinion in infectious diseases Coffin et al., 1986 journal Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P 1986 May 1-7 321 6065 10 Nature Cristillo et al., 2011 journal Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R 2011 92 Pt 1 128-140 The Journal of general virology Dale et al., 2004 journal Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ 2004 78 24 13819-13828 Journal of virology Davis et al., 2002 journal Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE 2002 Apr-May 53 4-5 209-11 IUBMB life Deng et al., 1996 journal Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR 1996 Jun 20 381 6584 661-6 Nature Denis-Mize et al., 2000 journal Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G 2000 7 24 2105-2112 Gene therapy Duerr et al., 2012 journal Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN 2012 206 2 258-266 The Journal of infectious diseases Durier et al., 2006 journal Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP 2006 Apr 24 20 7 1039-49 AIDS (London, England) Flatz et al., 2012 journal Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ 2012 86 15 7760-7770 Journal of virology Franco et al., 2010 journal Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD 2010 28 35 5676-5685 Vaccine Gu et al., 2010 journal Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI 2010 5 9 PloS one Gudmundsdotter et al., 2009 journal Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B 2009 27 33 4468-4474 Vaccine Hammer et al., 2009 website Scott Hammer, Magdalena Sobieszczyk, Michael Yin 2009 http://www.clinicaltrials.gov/ct2/show/NCT00865566?term=Ad5+DNA&rank=3 Hanke et al., 2002 journal Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A 2002 21 1-2 108-114 Vaccine Harris et al., 1996 journal Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT 1996 14 10 971-976 Vaccine Harro et al., 2009 journal Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV 2009 25 1 103-114 AIDS research and human retroviruses Hawkins et al., 2003 journal Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN 2003 21 13-14 1548-1553 Vaccine Hejdeman et al., 2004 journal Hejdeman B, Boström AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, Sandström E, Bratt G, Wahren B 2004 20 8 860-870 AIDS research and human retroviruses Hirao et al., 2008 journal Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB 2008 26 25 3112-3120 Vaccine Johnson et al., 2012 journal Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Loré K, Gall JG, Gostick E, Lefebvre F, Cameron MJ, Price DA, Haddad E, Sekaly RP, Seder RA, Koup RA 2012 188 12 6109-6118 Journal of immunology (Baltimore, Md. : 1950) Kaneko et al., 2000 journal Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D 2000 267 1 8-16 Virology Kang et al., 2003 journal Kang KK, Choi SM, Choi JH, Lee DS, Kim CY, Ahn BO, Kim BM, Kim WB 2003 46 5 270-276 Intervirology Kent et al., 2007 journal Kent S, De Rose R, Rollman E 2007 Feb 8 2 159-67 Current opinion in investigational drugs (London, England : 2000) Kim et al., 1998 journal Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB 1998 28 3 1089-1103 European journal of immunology Kim et al., 2000 journal Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB 2000 74 7 3427-3429 Journal of virology Kim et al., 2001 journal Kim JJ, Yang JS, Manson KH, Weiner DB 2001 19 17-19 2496-2505 Vaccine Knight et al., 1990 journal Knight SC, Macatonia SE, Patterson S 1990 6 2-3 163-75 International reviews of immunology Kutzler et al., 2005 journal Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB 2005 175 1 112-123 Journal of immunology (Baltimore, Md. : 1950) Kwa et al., 2014 journal Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR 2014 Journal of virology Leclerc et al., 1997 journal Leclerc C, Dériaud E, Rojas M, Whalen RG 1997 179 2 97-9106 Cellular immunology Lekutis et al., 1997 journal Lekutis C, Shiver JW, Liu MA, Letvin NL 1997 158 9 4471-4477 Journal of immunology (Baltimore, Md. : 1950) Lena et al., 2002 journal Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P 2002 20 Suppl 4 A69-79 Vaccine Li et al., 2008 journal Li W, Li S, Hu Y, Tang B, Cui L, He W 2008 26 26 3282-3290 Vaccine Liu et al., 2004 journal Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y 2004 Sep 18 3 251-4 Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology Liu et al., 2006 journal Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL 2006 Apr 12 24 16 3332-9 Vaccine Locher et al., 2004 journal Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA 2004 22 17-18 2261-2272 Vaccine Lu et al., 2000 journal Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J 2000 Jul 5 97 14 8027-32 Proceedings of the National Academy of Sciences of the United States of America MacGregor et al., 1998 journal MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB 1998 178 1 92-9100 The Journal of infectious diseases MacGregor et al., 2005 journal MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB 2005 23 17-18 2066-2073 Vaccine Malm et al., 2005 journal Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V 2005 18 4 678-88 Viral immunology Mascola et al., 2005 journal Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL 2005 79 2 771-779 Journal of virology McElrath et al., 2008 journal McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR 2008 372 9653 1894-1905 Lancet McEvers et al., 2005 journal McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H 2005 Jul 14 23 32 4128-35 Vaccine Moore et al., 2002 journal Moore AC, Kong WP, Chakrabarti BK, Nabel GJ 2002 76 1 243-250 Journal of virology O'Hagan et al., 2001 journal O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB 2001 75 19 9037-9043 Journal of virology Otero et al., 2004 journal Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB 2004 22 13-14 1782-1790 Vaccine Otten et al., 2005 journal Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB 2005 Jul 79 13 8189-200 Journal of virology Ozpolat et al., 1998 journal Ozpolat B, Rao XM, Powell MF, Lachman LB 1998 14 5 409-417 AIDS research and human retroviruses Pal et al., 2005 journal Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P 2005 34 5-6 226-236 Journal of medical primatology Pal et al., 2006 journal Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S 2006 348 2 341-353 Virology Palella et al., 1998 journal Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD 1998 Mar 26 338 13 853-60 The New England journal of medicine Parker, 2007 website Scott Parker 2007 http://clinicaltrials.gov/ct2/show/NCT00528489 Patterson et al., 2000 journal Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M 2000 14 16 2445-2455 AIDS (London, England) Pegu et al., 2013 journal Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G 2013 87 3 1708-1719 Journal of virology Peters et al., 2007 journal Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J 2007 25 11 2120-2127 Vaccine Qiu et al., 1999 journal Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF 1999 73 11 9145-9152 Journal of virology Rerks-Ngarm et al., 2009 journal Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH 2009 361 23 2209-2220 The New England journal of medicine Reynolds et al., 2012 journal Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI 2012 30 30 4465-4475 Vaccine Robinson et al., 2006 journal Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR 2006 352 2 285-294 Virology Santra et al., 2004 journal Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL 2004 Jul 27 101 30 11088-93 Proceedings of the National Academy of Sciences of the United States of America Sheets et al., 2006 journal Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL 2006 91 2 610-619 Toxicological sciences : an official journal of the Society of Toxicology Shiver et al., 2002 journal Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA 2002 Jan 17 415 6869 331-5 Nature Sizemore et al., 1995 journal Sizemore DR, Branstrom AA, Sadoff JC 1995 270 5234 299-302 Science (New York, N.Y.) Song et al., 2006 journal Song R, Liu S, Adams RJ, Leong KW 2006 26 6 380-389 Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research Stieneker et al., 1991 journal Stieneker F, Kreuter J, Löwer J 1991 5 4 431-435 AIDS (London, England) Sun et al., 2013 journal Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Zhu W, Chen L, Zhang L 2013 87 10 5669-5677 Journal of virology Takehisa et al., 2001 journal Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M 2001 Aug 10 17 12 1143-54 AIDS research and human retroviruses Tatalick et al., 2005 journal Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P 2005 Apr 8 23 20 2628-38 Vaccine Vecino et al., 2002 journal Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ 2002 82 3 197-204 Immunology letters Vinner et al., 1999 journal Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A 1999 17 17 2166-2175 Vaccine Walther-Jallow et al., 2001 journal Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R 2001 82 Pt 7 1601-1612 The Journal of general virology Wang et al., 1993 journal Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB 1993 90 9 4156-4160 Proceedings of the National Academy of Sciences of the United States of America Wang et al., 1993 journal Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanan M, Gilbert L 1993 12 9 799-805 DNA and cell biology Wang et al., 2006 journal Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S 2006 24 21 4531-4540 Vaccine Weber et al., 2001 journal Weber R, Bossart W, Cone R, Luethy R, Moelling K 2001 20 11 800-803 European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology Xin et al., 2005 journal Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K 2005 Dec 12 24 1769-77 Gene therapy Yoshino et al., 2004 journal Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR 2004 173 11 6850-6857 Journal of immunology (Baltimore, Md. : 1950) Zhang et al., 2009 journal Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, McMichael A, Jiang S 2009 284 14 9184-9191 The Journal of biological chemistry